经酒精和微波联合治疗原发性肝癌的临床研究及超声造影在联合治疗中的作用
|
摘要
第一章超声造影在原发性肝癌滋养动脉检测中的价值
目的采用超声造影对原发性肝癌滋养动脉进行检测，以探讨超声造影在原发性肝癌滋养动脉检测中的作用及其临床意义。
方法采用超声造影对比脉冲序列(CPS)造影成像技术对72例原发性肝癌患者进行检查，观察肿块滋养动脉供血情况，并与彩色多普勒超声进行比较。同时运用超声造影对肿块滋养动脉的供血方式进行分型；运用超声造影对肿块滋养动脉的内径进行测量，比较1～3cm组、～5cm组和～8cm组三组间肿块滋养动脉的内径粗细有无差别。
结果超声造影检出肿块滋养动脉68例(94.4％)，而彩色多普勒超声检出肿块滋养动脉者38例(52.8％)，超声造影对肿块滋养动脉检出率明显高于彩色多普勒超声(P＜0.05)。超声造影可将滋养动脉分为包绕型和分支型两型，以DSA作为标准对照，超声造影分型的准确性为93.3％。Kappa值为0.86。肝肿块滋养动脉内径1～3am组明显小于～5cm组(P＜0.05)，～5cm组明显小于～8cm组(P＜0.05)。随着肿块直径的增大，滋养动脉内径也常随之增大。
结论超声造影能较好地显示原发性肝癌的滋养动脉，是一种非常敏感的微血管检测技术，具有非常重要的临床意义。
第二章超声引导下经酒精和微波联合治疗原发性肝癌的临床研究
目的：通过采用无水酒精+微波及无水酒精+微波阻断滋养动脉+微波联合治疗原发性肝癌，探讨联合治疗在原发性肝癌治疗中的价值。
方法：将40例患者48个直径2～5cm原发性肝癌病灶分成三组进行介入消融治疗。Ⅰ)微波治疗组(肿块平均直径3.2cm)；Ⅱ)无水酒精+微波治疗组(肿块平均直径3.4cm)；Ⅲ)无水酒精+微波阻断滋养动脉+微波治疗组(肿块平均直径3.3cm)。术后运用增强CT测量肿块凝固最大横径，并评估三组肿块完全坏死率。
结果：Ⅰ组肿块凝固最大横径为28±4.6mm、完全坏死率为58.8％(10／17)；Ⅱ组肿块凝固最大横径为36±8.3mm，完全坏死率为73.4％(11／15)；Ⅲ组肿块凝固最大横径为46±8.5mm，完全坏死率为93.8％(15／16)。其中Ⅱ组肿块凝固最大横径及完全坏死率要明显高于Ⅰ组(P＜0.001，P＜0.05)；Ⅲ组肿块凝固最大横径及完全坏死率要明显高于Ⅱ组(P＜0.001，P＜0.05)。三组间主要并发症发生率无明显差异(P＞0.05)。
结论：采用无水酒精和微波联合治疗原发性肝癌，尤其是无水酒精+微波阻断滋养动脉+微波联合治疗原发性肝癌能明显提高肿瘤的灭活范围和完全坏死率。
目的比较超声造影和增强螺旋CT对原发性肝癌非手术治疗疗效的评判能力，探讨超声造影在原发性肝癌非手术治疗评估中的价值。
方法对56例(64灶)经超声引导穿刺活检病理确诊的原发性肝癌患者进行非手术治疗。其中采用TACE 4例、PEI8例、PMCT11例、RFA5例、TACE+PEI4例、TACE+PMCT3例、PEI+PMCT11例、PEI+微波阻断滋养动脉+PMCT10例。非手术治疗后分别进行了超声造影和增强螺旋CT检查，以判断肿瘤的灭活程度，并对两者的判别能力进行分析比较。
结果超声造影发现46个病灶没有增强(46／64)，18个病灶有部分增强(18／64)。增强螺旋CT发现48个病灶没有增强(48／64)，16个病灶有部分增强(16／64)。与临床追踪对照，超声造影和增强螺旋CT对非手术治疗疗效判定的敏感性、特异性及准确率分别为94.4％、97.8％、96.9％和83.3％、97.8％、93.8％。两种方法比较差异无显著性意义(P＞0.05)。
结论超声造影评估原发性肝癌非手术治疗效果与增强螺旋CT相近，是判定非手术治疗效果的一种敏感而有效的方法。对于行TACE治疗及少数血供不是特别丰富的病灶，超声造影具有较增强螺旋CT更重要的临床价值。
Part one Value of contrast-enhanced ultrasonography in detection of feeding artery of hepatocellular carcinoma
Objective To evaluate value of contrast-enhanced ultrasonography(CEUS) in detection of feeding artery of hepatocellular carcinoma(HCC).
Methods CEUS were performed on 72 patients with HCC to detect feeding artery. The blood flow image of feeding artery was observed and was compared with color Doppler sonography.And the type and diameter of feeding artery were also observed with CEUS.
Results A feeding artery was detected in 68 HCCs(94.4%) with CEUS,A feeding artery was detected in 38 HCCs(52.8%) with color Doppler sonography(P＜0.05). The feeding artery of HCCs could be classified into surrounding artery pattern or branching artery pattern.Compared with DSA, the accuracy of CEUS was 93.3% for detecting the feeding artery patterns. Kappa value was 0.86. The diameter of feeding artery in 1～3cm HCCs was smaller than in～5cm HCCs(P＜0.05), the diameter of feeding artery in the～5cm groups was smaller than in the～8cm HCCs (p＜0.05).
Conclusion CEUS can image the feeding artery very well,and is a very sensitive technique of detecting micro-vessel, has very important clinical value. Part two Hepatocellular carcinoma ablation by combining percutaneous microwave coagulation therapy and ethanol injection
Objective We sought to determine if larger hepatocellular carcinoma(HCC) ablative volumes could be obtained by combining percutaneous microwave coagulation therapy(PMCT) and ethanol injection(PEI), by PEI followed by PMCT with occlusion of the feeding artery.
Methods Forty patients with 48 HCCs(diameter,2-5cm) were treated with (Ⅰ) percutaneous microwave coagulation therapy; (Ⅱ) combined therapy of PEI immediately followed by PMCT; (Ⅲ) combined therapy of PEI immediately followed by PMCT with occlusion of the feeding artery. The coagulated area was measured at the maximum diameter perpendicular to the needle tract on enhanced computed tomography (CT) performed immediately after therapy. The local effect of the treatment was evaluated by follow-up enhanced CT.and the rate of complete necrosis were compared with three treatment groups.
Results The coagulation area in groupⅠwere 28±4.6mm, the rate of complete necrosis in groupⅠwere 58.8%(10/17); The coagulation area in groupⅡwere 36±8.3mm, the rate of complete necrosis in groupⅡwere 73.4%(11/15); the coagulation area in groupⅢwere 46±8.5mm, the rate of complete necrosis in groupⅢwere 93.8%(15/16). The difference in the coagulation area and the rate of necrosis were significantly larger in the groupⅡthan groupⅠ(p＜0.001,p＜0.05). Thedifference in the coagulation area and the rate of necrosis were significantly larger in groupⅢthan groupⅡ(p＜0.001,p＜0.05).
Conclusions Combined therapy of PEI immediately followed by PMCT, especially combined therapy of PEI immediately followed by PMCT with occlusion of the feeding artery can significantly coagulate larger volumes of tumor and improve the rate of complete necrosis. Part three Evaluation of non-surgical treatment response in hepatocellular carcinomas using contrast-enhanced sonography: comparison with contrast-enhanced helical CT
Objective: To compare the efficacy of contrast-enhanced sonography with contrast-enhanced helical CT for non-surgical treatment response in hepatocellular carcinomas.
Materials and Methods: Non-surgical therapies were performed on 56 patients with 64 liver neoplasms. Including 4 patients performing TACE, eight patients performing PEI,eleven patients performing PMCT, five patients performing RFA, four patients performing TACE+PEI, three patients performing TACE+PMCT, eleven patients performing PEI+PMCT, ten patients performing PEI+occlusion of the feeding artery +PMCT, and diagnosies were made before non-surgical therapies by US-guided biopsy. Sono Vue enhanced ultrasonography and contrast-enhanced helical CT were performed to assessing the treatment response.
Results: Forty-six of 64 lesions were not enhanced with contrast-enhanced sonography.Partial enhancement were demonstrated in 18 lesions. Forty-eight of 64 lesions were not enhanced with contrast- enhanced helical CT.Partial enhancement were demonstrated in 16 lesions.The sensitivity、specificity and accuracy were 94.4%、97.8%、96.9% for contrast-enhanced sonography and 83.3%、97.8%、93.8% for contrast-enhanced helical CT compared with clinic(P＞0.05). There were no significant differences between contrast-enhanced sonography and contrast-enhanced helical CT.
Conclusion: Contrast-enhanced sonography is at least comparable with contrast-enhanced helical CT in assessing the non-surgical treatment response in hepatocellular carcinomas and is more sensitive and useful in assessing treatment response of TACE and some patents without residue tumors with contrast-enhanced helical CT.
目的采用超声造影对原发性肝癌滋养动脉进行检测，以探讨超声造影在原发性肝癌滋养动脉检测中的作用及其临床意义。
方法采用超声造影对比脉冲序列(CPS)造影成像技术对72例原发性肝癌患者进行检查，观察肿块滋养动脉供血情况，并与彩色多普勒超声进行比较。同时运用超声造影对肿块滋养动脉的供血方式进行分型；运用超声造影对肿块滋养动脉的内径进行测量，比较1～3cm组、～5cm组和～8cm组三组间肿块滋养动脉的内径粗细有无差别。
结果超声造影检出肿块滋养动脉68例(94.4％)，而彩色多普勒超声检出肿块滋养动脉者38例(52.8％)，超声造影对肿块滋养动脉检出率明显高于彩色多普勒超声(P＜0.05)。超声造影可将滋养动脉分为包绕型和分支型两型，以DSA作为标准对照，超声造影分型的准确性为93.3％。Kappa值为0.86。肝肿块滋养动脉内径1～3am组明显小于～5cm组(P＜0.05)，～5cm组明显小于～8cm组(P＜0.05)。随着肿块直径的增大，滋养动脉内径也常随之增大。
结论超声造影能较好地显示原发性肝癌的滋养动脉，是一种非常敏感的微血管检测技术，具有非常重要的临床意义。
第二章超声引导下经酒精和微波联合治疗原发性肝癌的临床研究
目的：通过采用无水酒精+微波及无水酒精+微波阻断滋养动脉+微波联合治疗原发性肝癌，探讨联合治疗在原发性肝癌治疗中的价值。
方法：将40例患者48个直径2～5cm原发性肝癌病灶分成三组进行介入消融治疗。Ⅰ)微波治疗组(肿块平均直径3.2cm)；Ⅱ)无水酒精+微波治疗组(肿块平均直径3.4cm)；Ⅲ)无水酒精+微波阻断滋养动脉+微波治疗组(肿块平均直径3.3cm)。术后运用增强CT测量肿块凝固最大横径，并评估三组肿块完全坏死率。
结果：Ⅰ组肿块凝固最大横径为28±4.6mm、完全坏死率为58.8％(10／17)；Ⅱ组肿块凝固最大横径为36±8.3mm，完全坏死率为73.4％(11／15)；Ⅲ组肿块凝固最大横径为46±8.5mm，完全坏死率为93.8％(15／16)。其中Ⅱ组肿块凝固最大横径及完全坏死率要明显高于Ⅰ组(P＜0.001，P＜0.05)；Ⅲ组肿块凝固最大横径及完全坏死率要明显高于Ⅱ组(P＜0.001，P＜0.05)。三组间主要并发症发生率无明显差异(P＞0.05)。
结论：采用无水酒精和微波联合治疗原发性肝癌，尤其是无水酒精+微波阻断滋养动脉+微波联合治疗原发性肝癌能明显提高肿瘤的灭活范围和完全坏死率。
目的比较超声造影和增强螺旋CT对原发性肝癌非手术治疗疗效的评判能力，探讨超声造影在原发性肝癌非手术治疗评估中的价值。
方法对56例(64灶)经超声引导穿刺活检病理确诊的原发性肝癌患者进行非手术治疗。其中采用TACE 4例、PEI8例、PMCT11例、RFA5例、TACE+PEI4例、TACE+PMCT3例、PEI+PMCT11例、PEI+微波阻断滋养动脉+PMCT10例。非手术治疗后分别进行了超声造影和增强螺旋CT检查，以判断肿瘤的灭活程度，并对两者的判别能力进行分析比较。
结果超声造影发现46个病灶没有增强(46／64)，18个病灶有部分增强(18／64)。增强螺旋CT发现48个病灶没有增强(48／64)，16个病灶有部分增强(16／64)。与临床追踪对照，超声造影和增强螺旋CT对非手术治疗疗效判定的敏感性、特异性及准确率分别为94.4％、97.8％、96.9％和83.3％、97.8％、93.8％。两种方法比较差异无显著性意义(P＞0.05)。
结论超声造影评估原发性肝癌非手术治疗效果与增强螺旋CT相近，是判定非手术治疗效果的一种敏感而有效的方法。对于行TACE治疗及少数血供不是特别丰富的病灶，超声造影具有较增强螺旋CT更重要的临床价值。
Part one Value of contrast-enhanced ultrasonography in detection of feeding artery of hepatocellular carcinoma
Objective To evaluate value of contrast-enhanced ultrasonography(CEUS) in detection of feeding artery of hepatocellular carcinoma(HCC).
Methods CEUS were performed on 72 patients with HCC to detect feeding artery. The blood flow image of feeding artery was observed and was compared with color Doppler sonography.And the type and diameter of feeding artery were also observed with CEUS.
Results A feeding artery was detected in 68 HCCs(94.4%) with CEUS,A feeding artery was detected in 38 HCCs(52.8%) with color Doppler sonography(P＜0.05). The feeding artery of HCCs could be classified into surrounding artery pattern or branching artery pattern.Compared with DSA, the accuracy of CEUS was 93.3% for detecting the feeding artery patterns. Kappa value was 0.86. The diameter of feeding artery in 1～3cm HCCs was smaller than in～5cm HCCs(P＜0.05), the diameter of feeding artery in the～5cm groups was smaller than in the～8cm HCCs (p＜0.05).
Conclusion CEUS can image the feeding artery very well,and is a very sensitive technique of detecting micro-vessel, has very important clinical value. Part two Hepatocellular carcinoma ablation by combining percutaneous microwave coagulation therapy and ethanol injection
Objective We sought to determine if larger hepatocellular carcinoma(HCC) ablative volumes could be obtained by combining percutaneous microwave coagulation therapy(PMCT) and ethanol injection(PEI), by PEI followed by PMCT with occlusion of the feeding artery.
Methods Forty patients with 48 HCCs(diameter,2-5cm) were treated with (Ⅰ) percutaneous microwave coagulation therapy; (Ⅱ) combined therapy of PEI immediately followed by PMCT; (Ⅲ) combined therapy of PEI immediately followed by PMCT with occlusion of the feeding artery. The coagulated area was measured at the maximum diameter perpendicular to the needle tract on enhanced computed tomography (CT) performed immediately after therapy. The local effect of the treatment was evaluated by follow-up enhanced CT.and the rate of complete necrosis were compared with three treatment groups.
Results The coagulation area in groupⅠwere 28±4.6mm, the rate of complete necrosis in groupⅠwere 58.8%(10/17); The coagulation area in groupⅡwere 36±8.3mm, the rate of complete necrosis in groupⅡwere 73.4%(11/15); the coagulation area in groupⅢwere 46±8.5mm, the rate of complete necrosis in groupⅢwere 93.8%(15/16). The difference in the coagulation area and the rate of necrosis were significantly larger in the groupⅡthan groupⅠ(p＜0.001,p＜0.05). Thedifference in the coagulation area and the rate of necrosis were significantly larger in groupⅢthan groupⅡ(p＜0.001,p＜0.05).
Conclusions Combined therapy of PEI immediately followed by PMCT, especially combined therapy of PEI immediately followed by PMCT with occlusion of the feeding artery can significantly coagulate larger volumes of tumor and improve the rate of complete necrosis. Part three Evaluation of non-surgical treatment response in hepatocellular carcinomas using contrast-enhanced sonography: comparison with contrast-enhanced helical CT
Objective: To compare the efficacy of contrast-enhanced sonography with contrast-enhanced helical CT for non-surgical treatment response in hepatocellular carcinomas.
Materials and Methods: Non-surgical therapies were performed on 56 patients with 64 liver neoplasms. Including 4 patients performing TACE, eight patients performing PEI,eleven patients performing PMCT, five patients performing RFA, four patients performing TACE+PEI, three patients performing TACE+PMCT, eleven patients performing PEI+PMCT, ten patients performing PEI+occlusion of the feeding artery +PMCT, and diagnosies were made before non-surgical therapies by US-guided biopsy. Sono Vue enhanced ultrasonography and contrast-enhanced helical CT were performed to assessing the treatment response.
Results: Forty-six of 64 lesions were not enhanced with contrast-enhanced sonography.Partial enhancement were demonstrated in 18 lesions. Forty-eight of 64 lesions were not enhanced with contrast- enhanced helical CT.Partial enhancement were demonstrated in 16 lesions.The sensitivity、specificity and accuracy were 94.4%、97.8%、96.9% for contrast-enhanced sonography and 83.3%、97.8%、93.8% for contrast-enhanced helical CT compared with clinic(P＞0.05). There were no significant differences between contrast-enhanced sonography and contrast-enhanced helical CT.
Conclusion: Contrast-enhanced sonography is at least comparable with contrast-enhanced helical CT in assessing the non-surgical treatment response in hepatocellular carcinomas and is more sensitive and useful in assessing treatment response of TACE and some patents without residue tumors with contrast-enhanced helical CT.
引文
[1] El-Serag HB,Mason AC:Rising incidence of hepatocellular carcinoma in the United states. N Engl J Med, 1999, 340:745-750
[2] Takano S, Oishi H, Kono S, et al. Retrospective analysis of type of hepatic resection for hepatocellular carcinoma. Br J Surg, 2000, 87:65-70
[3] Cance WG, Stewart AK, Menck HR. The national cancer database report on treatment patterns for hepatocellular carcinomas: Improved survival of surgically resected patients,1985-1996. Cancer, 2000,88:912-920
[4] Gannon CJ, Curley SA. The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors. Semin Radiat Oncol, 2005, 15:265-272
[5] Castells A, Brujx J, Bru C, et al. Treatmentment of smallhepato-cellular carcinoma in cirrhotic patients:acohort study comparing surgical resection and percutaneous ethand jection. Hepatology, 1993, 18:1121-1126
[6] Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. J Hepatol, 2001, 35:421-430
[7] Dong BW, Zhang J, Liang P, et al. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia, 2003, 19(2): 119-33
[8] Zhang J, Dong B, Liang P, et al. Significance of changes in local immunity in patients with hepatocellular carcinoma after percutaneous microwave coagulation therapy. Chin Med J(Engl), 2002,115(9):1367-1371
[9] Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonocally guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer, 1994, 74(3) :817-825
[10] Liang JD, Yang PM, Huang GT, et al. Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma. J Formos Med Assoc, 2004, 103(12): 908-13
[11] Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol, 2003, 9(9): 1885-91
[12] Chen MS, Li JQ, Zheng Y, et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Ann Surg, 2006,243: 321-328
[13] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 2003, 37:429-442
[14] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology, 2004,40:1352-1360
[15] Lu MD, Yin XY, Xie XY, et al. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg, 2005, 92(11): 1393-1398
[16] Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma, comparison with percutaneous ethanol injecton therapy. Cancer, 1999,85 (8):1694-1702
[17] Isozaki T, Numata K, Kiba T, et al. Differential Diagnosis of Hepatic Tumors by Using Contrast Enhancement Patterns at US. Radiology, 2003, 229(12): 798-805
[18] Herbay AV, Vogt C, Willers R, et al. Real-time Imaging With the Sonographic Contrast Agent SonoVue: Differentiation Between Benign and Malignant Hepatic Lesions. Ultrasound Med, 2004,23(12):1557-1568
[19] Albrecht T, Blomley M, Burns P, et al. Improved detection of hepatic metastases with pulse inversion US during the liver specific phase of SH USO8A : multicenter study[J].Radiology, 2003,227(2):361-370
[20] 陈敏华，杨薇，严昆等．超声造影对确定肝癌射频消融范围及治疗策略的应用价值．中华超声影像学杂志，2006，15(3)：193-197
[21] Okudu K. Hepatocellar carcinoma:clinicopathological aspects. J Gastroentrol Hepatol, 1997,12(9-10):S314
[22] Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver directed therapy. J Vasc Interv Radiol 2005; 6:911-935
[23] Song SY, Chung JW, Lim HG, et al. Nonhepatic Arteries Originating from the Hepatic Arteries: Angiographic Analysis in 250 Patients. Journal of Vascular & Interventional Radiology, 2006,17(3):461-469
[24] Imanura M, Shiratori Y, Shiina S, et al. Power Doppler sonography for hepatocellularcarcinomaLfactors affecting power Doppler signals of the tumor. Eur J Radiol, 1998,27:S157-160
[25] Madjar H, Prompler HJ, Del Favero V, et al. A new Doppler signal enhancing agent for flow assessment in breast lesions.European Journal of Ultrasound, 2000,12:123-130
[26] Quaiao E,Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material[J].Acad Radiol, 2003, 10(7):739-750
[27] Quaia E,Caliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble-contrast agent:diagnostic performance and confidence. Radiology, 2004, 232(2):420-430
[28] Okabe M. Patho-morphological studies on hepatocellular carcinoma:a study on a mechanism of capsule formation and septum formation of tumor nodule (Japanese). Acta Hepatol Jpn, 1979, 20:144 - 56
[29] Lirraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology, 2000, 214:761-768
[30] Livraghi T, Meloni F, Morabito A, et al. Multimodal image-guide tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl, 2004, 10 (suppll):S98 - S106
[31] Liang JD, Yang PM, Huang GT, et al. Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma. J Formos Med Assoc, 2004, 103(12): 908-913
[32] Horigome H, Nomura T, Saso K, et al. Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence. Am J Gastroenterol, 1999, 94: 1914 -1917
[33] Livraghi T, Goldberg SN, Lazzaroni S, et al. Radiofrequency ablation vs. ethanol injection in the treatment of small hepatocellular carcinoma. Radiology, 1999, 210:655 - 661
[34] De Baere T,Bessoud B,Dromain C,et al. Percutaneous radio- frequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol, 2002,178:53-59
[35] Washburn W. K, Dodd G.D Kohlmeier R.E et al. Radiofrequency tissue ablation: effect of hepatic blood flow occlusion on thermal injuries produced in cirrhotic livers[J].Annals of surgical oncology, 2003,10(7):773-777
[36] Bruix J, Sherman M, Llovet ]M, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol, 2001,35:421
[37] Liang JD, Yang PM, Huang GT, et al. Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma. J Formos Med Assoc, 2004, 103(12):908-913
[38] Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol, 2003, 9(9): 1885-1891
[39] Goldberg SN, Kruskal JB, Oliver BS, et al. Percutaneous tumor ablation:increased coagulation by combining radio-frequency ablation and ethanol instillation in a rat breast tumor model. Radiology, 2000, 217: 827-831
[40] Clark Timothy W.I, Soulen MC. Chemical ablation of hepatocellular carcinoma. J Vasc Interv Radiol, 2002,13:S245-S252
[41] Seki T, Tamai T, Nakagawa ZT, et al. Combination therapy with transcatherter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer, 2000, 89:1245-1251
[42] 姜晓龙，孙巍，贾奇志，等．超声引导微波热凝固结合肝动脉栓塞化疗治疗肝癌．中华超声影像学杂志，2002，11：13-15
[43] Shibata T, Murakami T, Ogata N. Percutaneous microwave coagulation therapy for patients with primary and metastatic hepatic tumors during interruption of hepatic blood flow. Cancer, 2000,88:302-311
[44] Murakami T, Shibata T, Inoue Y, et al. Percutaneous microwave tumor coagulation for hepatocellular carcinomas with interruption of segmental hepatic blood flow. J Vasc Interv Radiol, 2002,13:185-191
[45] Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma:an eastern point of view. Liver Transpl, 2004,10:S3-S8
[46] Dromain C, de Baere T, Elias D, et al. Detection and characterisation of liver metastases. Eur Radiol, 2004,14 Supp18:25-33
[47] Numata K, Tanaka K, Kiba T, et al. Contrast-enhanced, wide-band harmonic gray scale imaging of hepatocellular carcinoma: correlation with helical computed tomographic findings. J Ultrasound Med, 2001,20:89
[48] Quaiao E, Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material[J].Acad Radiol, 2003,10(7):739-750
[49] D'Onofrio M, Rozzanigo U, Masinielli BM, et al. Hypoechoic focal liver lesions: characterization with contrastenhanced ultrasonography. J Clin Ultrasound, 2005, 33(4): 164-172
[50] Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrastspecific imaging: back to gray scale in ultrasound. Eur Radiol, 2002, 12:151-165
[51] Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast specific US modes and a sulfur hexafluoride - filled microbubble contrast agent:diagnostic performance and confidence. Radiology, 2004,232:420 - 430
[52] Dietrich C F, Ignee A, Trojan J, et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut, 2004,53:401-405
[53] Maruyama H, Matsutani S, Saisho H, et al. Real-time blood-pool images of contrast enhanced ultrasound with definity in the detection of tumor nodules in the liver. Br J Radiol, 2005,78:512-518
[54] Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatmentwith radiofrequency ablation versus ethanol inject ion[J].Radiology, 1999,210(3):655-661
[55] Vallone P, Gallipoli A, Izzo F, et al. Local ablation procedures in primary liver tumors: Levovist US versus spiral CT to evaluate therapeutic results. Anticancer Res, 2003,23(6D):5075-5079
[56] 裴小青，李安华，韩峰等．超声造影成像对TACE综合治疗肝癌疗效的评判价值与螺旋CT对比分析．中国超声医学杂志，2005，21(10)：764-766
[1]Albrecht T, Mattrey RF. Tumar imaging with ultrasound contrast. In:Thomsen HS, Muller RN, Mattrey RF(eds) Trends in contrast media. Medical radiology:diagnostic imaging and radiation oncology series. Springer, Berlin Heidelberg New York, 1999,pp367-382
[2] Quaiao E, Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material[J]. Acad Radiol, 2003,10(7):739-750
[3] Ignee A, Weiper D, Schuessler G, et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z-Gastroenterol, 2005, 43(3): 289-294
[4] Borden MA, Kruse DE, Caskey CF, et al. Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction. IEEE Trans Ultrason Ferroelectr Freq Control, 2005, 52(11): 1992-2002
[5] Sonoda S,Tachibana K, Uchino E, et al. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles.Invest Ophthalmol Vis Sci, 2006, 47(2): 558-564
[6] Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol, 1968,3:356-366
[7] Schnerder M, Arditi M, BarrAu M B, et al.BRI:a new ultasonographic contrast agent based on sulfur hexafluoride-filled microbubbles[J]. Invest adiol, 1995,30(8) :451-457
[8] Bauer A, Blomey M, Leen E, et al. Liver-specific imaging with SHU563A:diagnostic potential of a new class of ultrasound contrast media. Eur Radial, 1999, 9(supple 3):S349-352
[9] Correas JM, Bridal L, Lesarre A, et al. Ultrasound contrast agent: properties, principles of action, tolerance and artifacts. Eur Radiol, 2001,11:1316-1328
[10] Schnerder M. SonoVue, a new ultrasound contrast agent. Eur Radiol, 1999, 9 (suppl 3):347-348
[11] Correas J-M, Bridal L, Lesavre A, Mejean A, et al. Ultrasound contrast agents: properties,principles of action, tolerance, and artifacts. Eur Radiol, 2001,11:1316-1328
[12] Bokor D, Chambers JB, Rees PJ, et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol, 2001, 36:104-109
[13] Kaps M, Seidel G,Bokor D,et al. Safety and ultrasound enhancing potentials of a new sulfur hexafluoride-containing agent in the cerebral circulation. J Neuroimaging, 1999,9:150-154
[14] Leen E, Angerson WJ, Yarmenitis, et al. Multi-centre clinical study evaluating the efficacy of SonoVue (BRI), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur Radiol, 2002, 41:200-206
[15] Madjar H, Prompler HJ, Del Favero V, et al.A new Doppler signal enhancing agent for flow assessment in breast lesions. European Journal of Ultrasound, 2000, 12:123-130
[16] Von Bibra H, Erne P, Bokor D, et al. SonoVue for left heart Doppler contrast enhancement:a phase II two-center study. Presented at the World Congress of Cardiology;RIO de Janeiro, Brazil,1998,4: 26-30
[17] Bogdahn U, Hoelscher T, Rosin L, et al. Contrast-enhanced trans-cranial and extracranial Duplex sonography:preliminary results of a multicenter phase II/III study with SonoVue. Echocardigraphy, 1999, 16 (2):761-766
[18] Dalla Palma L, Bertolotto M. Introduction to ultrasound contrast agent:physics overview. Eur Radiol, 1999, 9(Suppl 3):338-342
[19] De Jong N, Cornet R, Lancee CT. Higher harmonics of vibrating gas filled microspheres. Part one:Simulations. Ultrsonics, 1994,32:447-453
[20] Forsberg F, Goldberg BB, Liu JB, et al. Tissue-specific US contrast agent for evaluation of hepatic and splenic parenchyma. Radiology, 1999,210:125-132
[21] Barr R. Seeking consensus:contrast ultrasound in radiology. Eur J Radiol, 2002, 41:207-216
[22] Correas JM, Bridal L, Lesarre A, et al. Ultrasound contrast agent:properties, principles of action to lerance and artifacts. Eur Radiol, 2001,11:1316-1328
[23] Barr R. Seeking consensus:contrast ultrasound in radiology. Eur J Radiol, 2002,41:207-216
[24] Burns PN. Harmonic imaging with ultrasound contrast agents. Clinic Radiol, 1996,51:S50-S55
[25] Frinking PJA, Bouakaz A, Kirkhorn J, et al. Ultrasound contrast imaging:current and new potential. Ultrasound Med Biol, 2000,26(6): 965-975
[26] Hope Simpson D, Chin CT, Burns. Pulse inversion Doppler:a new method for detecting non-linear echoes from microbubble contrast agents. Frequency Control, 1999,46:372-382
[27] Verbeek XA, Ledoux LA, Willigers JM, et al. Experimental investigation of the pulse inversion technique for imaging ultrasound contrast imaging agents[J]. Jacoust Soc Am, 2000,107(4):2281-2290.
[28] Peter JA, Bouakaz A, Kirkhorn J, et al. Ultasound Contrast imaging: current and new potential methods. Ultrasound Med Riol, 2000, 26(6): 965-975
[29] Leene. Ultasound contrast harmonic imaging of abdominal organs. Sermin Ultrasound CT MRI, 2001,22(1):11-24
[30] Gaiani S, Celli N, Piscaglia F, et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol, 2004,41(3):421-426
[31] Lencioni R, Cioni D, Donati F, et al. SonoVue-enhanced C3-mode US imaging in the detection and characterization of focal liver lesions:a pilot clinical study. Eur Radiol, 2001,9:C4
[32] Luo BM, Wen YL, YangHY, et al. Differentiation between malignant and benign nodules in the liver: use of contrast C3-MODE technology. World J Gastroenterol, 2005,11(16):2402-2407
[33] Lee JY, Choi BI, Han JK, et al. Improved sonographic imaging of hepatic hemangioma with MR imaging. Ultrasound Med Biol, 2002,3:287-295.
[34] 陆兆龄，陈常佩．新型超声对比造影剂和成像技术在心脏以外领域中的应用[J]．中国医学影像技术，2001，17(9)：866-869
[35] Cosgrove DO, blomley MJK, Eckersley RJ, et al. Innovative contrast specific imaging with ultrasound[J].Electromedica, 2002,70:147-150
[36] Phillips RJ, Contrast pulse sequences(CPS):imaging nonlinear microbubbles[J]. IEEE Ultrasonic Symposium, 2001, 1739-1745
[37] Choi BI, Kim TY, Han JK, et al. Vascularity of hepatocellular carcinoma:assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. Radiology, 2000,214:381-386
[38] 王威琪，汪源源，余建国．医学超声中谐波技术的有关问题．世界医疗器械，1999，5(10)：30-34
[39] Shankar PM, Dala Krishna, et al. Advantages of subharmonic over second hamonics backscatter for contrast-to-tissue echo enhancement. Ultrasound Med Biol,1998,24:395-399
[40] Burns PN, Wilson SR, Kahlilik, Contrast-enhanced pulse inversion imaging of the liver with aperflurocarborn agent:protocol for the differential diagnosis of focal lesion. Radiology, 2000,217:458
[41] Atbrecht T, Urbank A, Mahler M, et al. Prolongation and optimization of Doppler enhancement with amicrobubble US contrast agent by using continuous infusion:preliminary experience. Radiology, 1998,207:339-347.
[42] Spinazzi A. Emerging clinical applications for contrast-enhanced ultrasonography. Eur Radiol, 2OOl, 11(Suppl 3):E7-E12
[43] Albrecht T, Hoffmann CW, Schettler S, et al. Improved detection of liver metastases with phase inversion imaging during the liver-specific phase of the ultrasound contrast agent Levovist. Eur Radiol, 1999,9(Suppl 3):388
[44] Kim TK, Choi .BI, Han JK, et al. Hepatic Tumors:contrast agentenhancement patterns with pulse-inversion harmonic US. Radiology,2000,216:411-417
[45] Bertolotto M, Dalla Palma L, Quaia E, et al. Characterization of unifocal liver lesions with pulse inverson harmonic imaging after Levovist injection:preliminary results. Eur Radiol, 2000,10:1369-1370
[46] Youk JH, Kim CS, Lee JM. Contrast-enhanced agent detection imaging:value in the characterization of focal hepatic lesions. J Ultrasound Med, 2003,22(9):897-910
[47] Quaia E, Caliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble-contrast agent:diagnostic performance and confidence. Radiology, 2004, 232 (2):420-430
[48] Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographic, 2004, 23(4):921-935
[49] Bauer A,Schlief R, Zomack M, et al. Acoustically stimulated microbubbles in diagnostic ultrasound:properties and implications for diagnostic use. In:Nanda N, Schlief R, Goldberg BB(eds)Advances in echo imaging using contrast enhancement, 2nd edn. Kluwer, Lancaster, England, 1997,pp9-19
[50] Hauff P, Fritzsch T, Reinhardt M, et al. Delineation of experimental liver tumors in rabbits by anew ultrasound contrast agent and stimulated acoustic emission. Invest Radiol, 1997, 32:94-99
[51] Bauer A, Blomley MJK, Leen E, et al. Liver specific imaging with SHU563 A:diagnostic potential of a new class of ultrasound contrast media. Eur Radiol, 1999, 9:S349-S352
[52] Takayasu K,Moriyama Y, Mzkuuchim. The diagnosis of smallhepato-cellular carcinomas:efficacy of various imaging procedure in 100 patients. Am J Roentgenol, 1990,55:49-54
[53] Dodii G, Miller W, Baron R. Detection of malignant tumors in endstage cirrhotic livers:efficacy of sonography as a screening technique. Am J Roentgenol, 1992,159:727-733
[54] Wernecke K, Rummency E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma:comparative sensitivities of sonography, CT,and MR imaging. AJR, 1991,157:731-739
[55] Kinkel K, lu Y, Both M, et al.Detection of hepatic metastases from cancer of the gastrointestinal tract by using noninvasive imaging methods(US, CT.Hrimaging, PET):a meta-anaysis. Radiology, 2002, 224:748-756
[56] Albrecht T, Hoffmann CW, Schmitz SA, et al. Phase-inversion sonography during the liver-specific late phase of contrast enhancement:improved detection of liver metastases. AJR. 176:1191-1198
[57] Palma LD. D iagnostic imaging and interventional therapy of hepatocellular carcinoma. Br J Radiol, 1998, 71(848):808
[58] Itoh Y, A kamatsu K. Relationships between echo level and histologic characteristics in small hepatocellular carcinomas. J Clin Ultrasound, 1998, 26(6):295
[59] Iwasaki M, Furuse J , Yosh inoM , et al. Sonograph ic appearances of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography. J Clin Ultrasound, 1998, 26 (6) : 303
[60] Hann LE, Bach AM, Cramer LD, et al. Hepatic sonography :comparison of tissue harmonic and standard songraphy techniques. AJR. 173:201-206
[61] Tanaka S, Oshikawa O, Sasaki T, et al. Evaluation of tissue harmonic imaging for diagnosis of focal liver lesions. Ultrasound Med Biol, 2000, 26:183-187
[62] Harvey CJ, Albrecht T. Ultrasound of focal liver hepatic lesions. Eur Radiol, 2001,11:1578-1593
[63] Koda M, Matsunage Y, Ueki M, et al. Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound:comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound[J]. Eur adiol, 2004,14:1100- 1108
[64] Nicolau C, Catala V, VilanaR, et al . Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent : correlation with cellular differentiation[J].Eur Radiol, 2004,14 (6):1092-1099
[65] Strobel D, Kleinecke C, Hansler J, et al. Contrast-enhanced sonography for the characterisation of hepatocellular carcinomas—-correlation with histological differentiation. Ultraschall Med, 2005, 26(4): 270-276
[66] Quaia E, Calliada F, Bertolotto M, et al. Characterization of focalliver lesions with contrast-specific US modes and a sulfur hexafluo-ride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology, 2004, 232(2):420-430
[67] Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics, 2004, 24(4):921-935.
[68] Solbiati L, Martegani A, Leen E, et al. Contrast-enhanced ultrasound of liver diseases. Milan : Springer, 2003, 44-87
[69] Youk JH, Kim CS, Lee JM. Contrast enhanced agent detection imaging[J]. J Ultrasound Med, 2003, 22(9):897-910
[70] Kim SH, Lee JM, Lee JM, et al. Value of contrast-enhanced sonography for the characterization of focal hepatic lesions in patients with diffuse liver disease: receiver operating characteristic analysis. AJR Am J Roentgenol, 2005,184(4):1077-1084
[71] von Herbay A, Vogt C, Willers R, et al. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med, 2004,23(12):1557-1568
[72] Isozaki T , Numata K, Kiba T , et al. Differential diagnosis of hepatic tumors by using contrast enhancement patterns at US. Radiology, 2003, 229(3):798-805
[73] Rabenandrasana HA, Furukawa A, Furuichi K, et al. Comparison between tissue harmonic imaging and liver-specific late-phase contrast-enhanced pulse-inversion imaging in the detection of hepatocellular carcinoma and liver metastasis. Radiat Med, 2004,22(2): 90-97
[74] Diet rich CF, Ignee A, Trojan J, et al . Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU508A[J]. Gut,2004, 53(3):401-405
[75] Bernatik T, Becker D, Neureiter D, et al. Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the liver. Eur J Gastroenterol Hepatol, 2004,16(3):313-317
[76] Wen YL, Kudo M, Zheng RQ, et al. Characterization of hepatic tumors:value of contrast-enhanced code phase-inversion harmonic angio[J]. AJR, 2004,182:1019-1026
[77] Dill-Macky MJ , Burns PN , Khalili K, et al . Focal Hepatic Masses: Enhancement Patterns with SHU508A and Pulse Inversion US[J]. Radiology, 2002, 222(1):95-102
[78] Uggowitzer MM, Kugler C, Mischinger HJ, et al. Echo - enhanced Doppler sonography of focal nodular hyperplasia of the liver [J].J Ultrasound Med, 1999, 18:445-451
[79] Solbiati L, Martegani A , Leen E , et al . Contrast-enhanced ultrasound of liver dieases[M]. Italia Milano: Springer-Ver-lag, 2003, 37-93
[80] Solbiati L , Martegani A , Leen E , et al . Contrast-enhanced ultrasound of liverdieases[M]. Italia Milano: Springer-Ver-lag, 2003, 37-93
[81] Solbiati L, Cova L, Lerace T, et al. The importance of arterial phase imaging for wadeband harmonic sonography for the characteriza of focal lesions in level cirrhosis using a second generation contrast agent. Radiology, 2000, 217:305
[82] Nishiharu T, Yamashita Y, Arakawa A, et al. Sonographic comparison of intraarterial C02 and helium microbubbles for detection of hepatocellular carcinoma: prelim inary observations. Radiology, 1998,206 (3): 767
[83] Dalla PL, Bertolotto M, Quaia E, et al. Detection of liver metastases with pulse inversion harmonic imaging:preliminary results. Eur Radiol, 1999,9(suppl 3):382-387
[84] Harvey CJ, Blomley MJ, Eckersley RJ, et al. Hepatic malignancies: improved detection with pulse-inversion US in late phase of enhancement with SHU 508-early experience. Radiology, 2000, 216:903-908
[85] Kim TK, Choi BI, Hong H, et al. Improved imaging of hepatic metastases with delayed pulse inversion harmonic imaging using a contrast SHU508A:preliminary study. Ultrasound Med Biol, 2000, 26:1439-1444
[86] Albrecht T, Hoffmann CW, Schettler S, et al. B-mode enhancement at phase-inversion US with air-based microbubble contrast agent:initial experience in humans. Radiology, 2000, 216:273-278
[87] Albrecht T, Blomley M, Golgberg B, et al. Detection of focal liver lesion with the new RES-specific echo contrast agent NC100100:results of an explorative multicenter study.Ultraschall Med,2000,21(suppl):24
[88] Oldenburg A, Hohmann J, Foert E, et al. Detection of hepatic metastases with low MI real time contrast enhanced sonography and SonoVue. Ultraschall Med, 2005,26(4):277-284
[89] Albrecht T, Blomley M, Burns P, et al. Improved detection of hepatic metastases with pulse inversion US during the liver specific phase of SH U508A : multicenter study[J]. Radiology, 2003, 227(2):361-370
[90] Castells A, Brujx J, Bru C, et al. Treatmentment of small hepatocellular carcinoma in cirrhotic patients:acohort study comparing surgicalresection and percutaneous ethand jection. Hepatology, 1993, 18: 1121-1126
[91] Nagao T, Inoue S, Yoshimi F, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg, 1990, 211:28 - 33
[92] Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg, 1991, 214:111-114
[93] Uchida H, Ohishi H, Matsui N, et al. Trancatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol,1990,13:140-145
[94] Livraghi T, Giorgio A, Marin G. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology, 1995,197:101 - 108
[95] Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer, 1994, 74:817 - 825
[96] Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol, 1996,167:759 - 768
[97] Amin Z, Donald JJ, Masters A, et al. Hepatic metastases: 7interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology, 1993,187:339 - 347
[98] Skjoldbye B, Pedersen MH, Struckmann J, Burcharth F, et al. Improved detection and biopsy of solid liver lesions using pulse-inversion ultrasound scanning and contrast agent infusion [J].Ultrasound Med & Biol,2002, 28 (4):439-444
[99] Oi H. Liver intervention. Nippon Igaku Hoshasen Gakkai Zasshi, 2000,60:826-832
[100] De Baere T, Bessoud B, Dromain C, et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol, 2002, 178:53-59
[101] Hsu HC, Wei TC, Tsang YM, et al. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepaticarterial embolization. Cancer, 1986, 57:1184-1191
[102] Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).Eur Radiol, 2005,14:1-9
[103] Minami Y, Kudo M, Kawasaki T, et al. Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol, 2004,183(1):153-156
[104] Shimizu M, Iijima H, Horibe T, et al. Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol Res,2004, 29 (4):235-242
[105] Vallone P, Gallipoli A, Izzo F, et al. Local ablation procedures in primary liver tumors: Levovist US versus spiral CTto evaluate therapeutic results. Anticancer Res, 2003, 23(6D):5075-5079
[106] Solbiati L, Lerace T,Tonolini M, et al. Guidance and control of percutaneous treatments with contrast-enhanced ultrasound[J]. Eur adiol, 2003,13(Suppl3):N87-N90
[107] Numata K, Isozaki T,Ozawa Y, et al. Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma[J].AJR,2003,180(1):143-149
[108] Solbiati L, Goldberg SN, Dellanoce M, et al. Radio-frequency ablation of hepatic metastases:postprocedural assessment with a US microbuble contrast agent-early experience. Radiology, 1999, 211(3): 643-649
[109] Zhou X, Strobel D, Haensler J, et al. Hepatic transit time: indicator of the therapeutic response to radiofrequency ablation of liver tumours.Br J Radiol, 2005,78(929):433-436
[110] Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet,1999,353 (9164):1579-1583
[111] Tamano M. Yoneda M. Kojima K,et al. Evaluation of esophageal varices using contrast-enhanced coded harmonic ultrasonography. Journal of Gastroenterology & Hepatology, 2004,19(5):572-575
[112] Michelle L, Therese M. The potential role of ultrasound contrast agents in the liver[J].Applied Radiology, 1997,26:13-18
[113] Lawrie A, Brisken AF, Francis SE, etal. Microbubble-enchanced ultrasound for vascular delivery. Gene Ther, 2000,7:2023-2027
[114] Unger EC , Matsunaga TO , McCreery TP , et al. Therapeutic applications of microbubbles. Eur J Radiol, 2002,42:160-168
[115] Huai L, Birnbaum Y, Fishbein TM, et al. Enhancement of thrombolysis in vivo without skin and soft tissue damage by transcutaneous ultrasound. Thromb Res, 1998,89:171-177
[116] 吴巍，宁新宝，姜藻，等．低功率超声辐射Levovist试剂致家兔肝脏微血管栓塞的研究．东南大学学报(自然科学版)，2003，33：399-402
[1] Duvoux C.Epidemiology and diagnosis of HCC in cirrhosis. Ann Chir, 1998, 52:511-7
[2] Bruix J, Castells A, Bru C. Caracteristicas clinicas y pronostico del carcinoma hepatocelular. Existen diferencias geograficas? Gastroenterol Hepatol,1991,14: 520-524
[3] Yoo HY,Patt CH,Geschwind JF,et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the united States between 1988 and2001: 5-year survival has improved significantly with time. J Clin Oncol, 2003,21: 4329-4235
[4] Goldstein HM, Wallace S, Anderson JH,et al. Transcatheter occlusion of abdominal tumors. Radiology, 1976, 120:539-545
[5] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology,2003, 37:429-442
[6] Bhattacharya S, Davidson B, Dhillon AP. Blood supply of early hepatocellular carcinoma. Semin Liver Dis, 1995,15:390-401
[7] Cohen SE, Safadi R, Verstandig A, et al. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig Dis Sci,1997, 42: 938-943
[8] Llovet JM, Real MI, Montana X, et al. Aterial embolisation or chemo-embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet,2002,359:1734-1739.
[9] Bronowick JD,Vetter D,Dumas F,et al.Transcatheter oily chemoembolization for hepatocellular carcinoma, cancer, 1994,74:16
[10] Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology, 1987,162:345-51
[11] Matsui O, Kadoya M, Yoshikawa J, et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate.Cancer Chemother Pharmacol, 1994,33(suppl):84-88
[12] Raoul JL, Heresbach D, Bretagne JF, et al. Chemoembolization of hepatocellular carcinomas. Cancer, 1992,70:585-590
[13] Fan J, Tang ZY, Yu Y, et al. Improved survival with resection after trancatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.Dig Surg 1998,15:674-678
[14] Kanai T,Hirohashi S,Upton MP,et al. Pathology of small hepatocellular carcinoma. Aproposal for a new gross classification.Cancer,1987, 60(4):810-819
[15] Choi BI,Kim HC,Han JK,et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings.Radiology,1992,182(3):709-713.
[16] Nishimura Y,Uhida H,Guo Q,et al.J Jpan Soc Cancer Ther, 1991,26:2279-2289
[17] Matsui O, Kadoya M, Yoshikawa J, et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol, 1994,33(suppl):84-88
[18] Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan.Hepatology,2000, 32:1224-1229
[19] Livraghi T, Giorgio A, Marin G, et al.Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology, 1995, 197:101-108
[20] Lencioni R, Pinto F, Armillotta N, et al.Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol, 1997,7:514-519
[21] Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jp J Clin Oncol, 1998, 28:604-608
[22] Orlando A, D'Antoni A, Camma C. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol,2000,95:2921-2927
[23] Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology,2000,32:1224-1229
[24] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology,2004, 40: 1352-1360
[25] Livraghi T, Meloni F, Morabito A, et al. Multimodal image-guide tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl,2004,10(suppl1): S98-S106
[26] Shiina S, Tagawa K, Unuma T, et al.Percutaneous ethanol injection therapy for hepatocellular carcinoma: a histopathologic study.Cancer, 1991,68:1524-1530
[27] Livraghi T, Lazzaroni S, Pellicano S,et al. Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia. AJR Am J Roentgenol,1993,161:1065-1069
[28] Livraghi T,Benedini V,Lazzaroni S,et al.Long-term results of single session percutaneous ethanol injection in patients with large hepatocellar carcinoma.Cancer, 1999,83:48-57
[29] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003, 362:1907-1917
[30] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology,2004,40: 1352— 1360
[31] Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology, 1998,27:67-72
[32] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology,2004,40: 1352- 1360
[33] Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guide tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl, 2004,10 (suppl1): S98-S106
[34] Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jp J Clin Oncol, 1998,28:604-608
[35] Daniele B,De Sio I, Izzo F,et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol, 2003, 36(1): 63-7
[36] Mazzanti R,Arena U,Pantaleo P,et al. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience. Canadian Journal of Gastroenterology, 2004,18(10):611-618
[37] Lin LW, Lin XY, He YM,et al. Experimental and clinical assessment of percutaneous hepatic quantified ethanol injection in treatment of hepatic carcinoma. World J Gastroenterol, 2004,10(21):3112-3117
[38] Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of longterm results after percutaneous ethanol injection therapy and surgical resection.Hepatology, 2001, 34:707-713
[39] Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection.Cancer, 1996, 77:1792-1796
[40] Khan KN, Yatsuhashi H, Yamasaki K,et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol,2000, 32:269-278
[41] Tanaka K,Nakamura S,Numata K,et al. Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization.Radiology, 1992,185(2):457-60
[42] Mc Gahan JP, Browning PD, Brock JM, et al. Hepatic ablation using radiofrequency electrocautery.Invest Radiol, 1990,25:267-270
[43] Rossi S, Fornari F, Paties C, et al.Thermal lesions induced by 480 kHz localized current field in guinea pig and in pig livers. Tumori, 1990,76:54-57
[44] Rossi S,Fornari F,Buscarini L.Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma.J Intervent Radiol, 1993,8:97-103
[45] Dickson JA, Calderwood SK. Temperature range and selective sensitivity of tumors to hyperthermia: a critical review. Ann NY Acad Sci, 1980,335:180-205
[46] Hill RP, Hunt JW. Hyperthermia. In: Tannock IF, Hill RP, eds.The Basic Science of Oncology. New York: Pergamon Press, 1987,337-357
[47] Haines DE, Watson DD, Halperin C. Characteristics of heat transfer and determination of temperature gradient and viability threshold during radiofrequency fulguration of isolated perfused canine right ventricle. Circulation, 1987,76:278-283
[48] Grundfest WS, Litvack FI, Doyle DL,et al. Laser-tissue interactions: considerations for cardiovascular applications. In:White RA, Grundfest WS, eds. Lasers in Cardiovascular Disease. Chicago: Yearbook Medical Publishers, 1987:32-43
[49] McGahan JP, Brock JM, Tesluk H, et al. Hepatic ablation with use of radiofrequency electrocautery in the animal model. J Vasc Interv Radiol, 1992,3:291-297
[50] 郑云，李锦清，陈敏山，等．气冷微波固化与传统微波固化杆温对治疗效应影响的比较研究．癌症，2004，23(11s)：1477—1481
[51] 广火田成也，安武晃一．肝癌对经皮的治疗—PEIT，MCT，RFA[J]．结合消化器，2002，7(5)：12-16
[52] Curley SA, Izzo ,F, Ellis L, et al. Radiofrequency ablation of malignant liver tumors in 304 patients. Proc Am Soc Clin Oncol,2000,19:248a
[53] Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Kadiat Oncol Biol Phys, 1979,5:235-242
[54] Curley SA ,Izzo F ,Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 cirrhotic patients. Ann Surg,2000,232:381-391
[55] Leveillee RJ, Hoey MF.Radiofrequency interstitial tissue ablation:wet electrode. J Endourol, 2003,17:563-577
[56] Rossi S, Buscarini E, Garbagnati F, et al.Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J oentgenol,1998,170: 1015-1022
[57] Gazelle GS, Goldberg SN, Solbiati L, et al.Tumor ablation with radio-frequency energy. Radiology, 2000,217:633-646
[58] Yamasaki T, Kurokawa F, Shirahashi H, et al. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow: comparison with standard percutaneous radiofrequency ablation therapy. Cancer, 2002,95:2353-2360
[59] Ikeda M, O kada S, U eno H, et al. Radiofrequency ablation and percutaeous ethanol injection in patients with small hepatocellualr carcinoma: a comparative study [J]. Jpn J Clin O ncol, 2001,31 (7):322-326
[60] Curdy SA, lzzo F, Ellis LM, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies, result in 123 patients [J]. Ann Surg, 1999,230(1): 1-8
[61] Liu LX, Jiang HC, Piao DX, et al. Radiofrequence ablation of liver cancers [J]. World J Gastroenterol,2002,8(3):393- 399
[62] Curely SA. Radiofrequency ablation of malignant liver tumors[J].Oncologist, 2001, 6(1):14-23
[63] Solbiati L , Golderg SN, lerace T, et al. Hepatic metastases: percutaneous radiofrequency ablation with cooled-tip electrodes [J]. Radiology, 1997,205(2): 367-373
[64] MachiJ, Uchida S, Sumida K, et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparo scopic and open surgical approaches [J]. J Gastrointest Surg,2001,5(5): 477-489
[65] Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol inject ion [J].Radiology, 1999, 210(3):655-661
[66] Tamai F, Furuse J , Maru Y, et al. Intrahepatic pseudoaneurysm: a complication following radiofrequency ablation therapy for hepatocellular carcinoma [J]. Eur J Radio 1, 2002,44(1):40-43
[67] Wong SL , Edwards MJ, Chao C, et al.Radiofrequency ablation for unresectable hepatic tumors [J]. Am J Surg, 2001,182 (2): 552-557
[68] Ng KK, Lam CM, POOh RT, et al. Portal vein thrombosis after radiofrequency ablation for recurrent hepatocellular carcinoma [J]. Asian J Surg,2003, 26 (1):50-53
[69] Livraghi T, Goldberg SN , Lazzaroni S, et al. hepatocellular carcinoma: radio-frequency ablation of medium and large lesions [J].Radiology,2000,214(3): 761-768
[70] Cutely SA, Izzo F,Delrio P, et al. Radiofrequency ablation of urtresectable primary and metastatic hepatic malignancies: result in 123 patients. Ann Surg,1999, 230(1):9-11
[71] Rossi S,Di Stasi M, Buscarini E,et al.Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol,1996, 167(3): 759-768
[72] Rossi S,Di Stasi M, Buscarini E ,et al. Percutaneous radioffequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am, 1995,1:73
[73] Wong SL, Edw ards MJ, Chao C, et al.Radiofrequency ablation for unresectable hepatic tumors [J]. Am J Surg, 2001,182(2): 552- 557
[74] 别府透，土居浩一，石河隆敏，他．大肠癌肝转移局所凝固疗法[J]．日本外科学会杂志，2001，102(5)：390-397
[75] Tateishi R, Shiina S,Teratani T,et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer, 2005, 103(6): 1201-9.
[76] Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology, 2005, 234:961-967
[77] Machi J, Bueno RS. Wong LL. Long-term Follow-up Outcome of Patients Undergoing Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma. World J surg,2005,29:1-10
[78] Chen MS, Li JQ, Zheng Y,et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Ann Surg, 2006,243: 321-328.
[79] Seki T, Wakabayashi M, Nakagawa T,et al.Percutaneous microwave coagulation therapy for patients w ith small hepatocellular carcinoma,comparison with percutaneous ethanol injecton therapy [J].Cancer, 1999,85(8): 1694-1702
[80] Ikeda M, Okada S,Ueno H,et al.Radiofrequency ablation and percutaeous ethanol injection inpatients with small hepatocellualr carcinoma: a comparative study[J].Jpn J Clin O ncol,2001,31(7):322-326
[81] Shinna S,TerataniT,ObiS,etal.Nonsurgicalt reatment of hepatocellular carcinoma:from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation[J].Oncolgy,2002,62(suppl):64-68
[82] Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma-4 cm.Gastroenterology, 2004, 127:1714-1723
[83] Shiina S, Teratani T, Obi S, et al. A randomized controlled study of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 2005,129:122-130
[84] Lin Sm, Lin CJ, Lin CC, et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma 3 cm or less. Gut, 2005,54:1151-1156
[85] Tabuse K.A new operative procedure of hepatic surgery using amicrowave tissue coagulator.Arch Jpn Chir, 1979,48(2): 160-172
[86] Seki T,Wakabayashi IVLNakagawa T,et al.Ultrasonocally guided percutaneous microwave coagulation therapy foe small hepatocellular carcinoma.Cancer,1994, 74 (3): 817-825
[87] Dong BW, Zhang J, Liang P, et al.Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma.Int J Hyperthermia, 2003, 19(2): 119-33
[88] Zhang J, Dong B,Liang P, et al.Significance of changes in local immunity in patients with hepatocellular carcinoma alter percutaneous microwave coagulation therapy.Chin Med J(Engl),2002,115(9)
[89] Sato M, Watanabe Y, Ueda S, et al.Microwave coagulation therapy for hepatocellular carcinoma.Gastroenterology, 1996,110 : 1507-1514
[90] Ido K, Isoda N, Kawamoto C, et al.Laparoscopic microwave coagulation therapy for solitary hepatocellular carcinoma performed under laparoscopic ultrasonograpgy. Gastrointest Endosc, 1997,45:415- 420
[91] Seki S; Sakaguchi H; Iwai S; et al.Five-year survival of patients with hepatocellular carcinoma treated with laparoscopic microwave coagulation therapy. Endoscopy,2005,37(12): 1220-1225
[92] 梁萍，董宝纬，于晓玲，等．双电极植入式微波辐射三维热场的研究．中华超声影像学杂志，1999，8(4)：255-插页2
[93] 张晶，董宝纬，梁萍，等．原发性肝癌经皮微波治疗前后局部免疫活性细胞功能检测．中华医学杂志，2001，81(16)：974-977
[94] Ohmoto K, Mimura N, Iguchi Y, et al. Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma on the surface of the liver. Hepatogastroenterology,2003, 50(53): 1547-51
[95] Takamura M, Murakami T, Shibata T, et al.Microwave Coagulation Therapy with Interruption of Hepatic Blood In- or Outflow:An Experimental Study. J Vasc Interv Radiol,2001,12:619-622
[96] Ishida T, Murakami T, Shibata T, Inou Y, et al.Percutaneous Microwave Tumor Coagulation for Hepatocellular Carcinomas with Interruption of Segmental Hepatic Blood Flow. J Vasc Interv Radiol, 2002,13:185-191
[97] Shibata T, Iimuro Y, Yamamoto Y, et al . Small hepatocellular carcinoma: Comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. Radiology,2002,223:331
[98] Goldberg SN. Comparison of techniques for image-guided ablation of focal liver tumors. Radiology,2002,223:304
[99] Dong B,Liang P, Yu X, et al.percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma:results in 234 patients.AJR, 2003, 180(6): 1547-1555
[100] Lu MD ,Chen JW, Xie XY, et al. Hepatocellular carcinoma:US-guided percutaneous microwave coagulation therapy.Radiology,2001,221:167-172
[101] Murakami R, Yoshimatsu S,Yamashita Y, et al. Treatment of hepatocellular carcinoma: value of percutanous microwave coagulation. AJR, 1995,164:1159-1164
[102] Sato M, Watanabe Y, Kashu Y, et al.Sequential percutaneous microwave coagulation therapy for liver tumor. Am J Surg, 1998,175(4):322-324
[103] Seki T, Tamai T, Nakagawa ZT, et al. Combination therapy with transcatherter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma.Cancer,2000,89:1245-1251
[104] 姜晓龙，孙巍，贾奇志，等．超声引导微波热凝固结合肝动脉栓塞化疗治疗肝癌．中华超声影像学杂志，2002，11：13-15
[105] Seki T,Wakabayashi M, Nakagawa T,et al.Percutaneous micrwave coagulation therapy for patients with small hepatocellular carcinoma:comparison with percutaneous ethanol injection therapy.Cancer, 1999, 85(8): 1694-1702
[106] Shibata T,Limuro Y, Yamamoto Y, et al. Small Hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy.Radiology,2002, 223:331-337
[107] Kurokochi K, Watanabe S, Masaki K, et al.Combined use of percutaneous ethanol injection and radiofrequcncy ablation for the effective treatment of hepatocellular carcinoma [J].lnt J Oncol,2002,21 (4):841-846
[108] Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol,2003,9(9): 1885-1891
[109] Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoemblization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy [J].Am Surg, 2002,68(9):828-831
[2] Takano S, Oishi H, Kono S, et al. Retrospective analysis of type of hepatic resection for hepatocellular carcinoma. Br J Surg, 2000, 87:65-70
[3] Cance WG, Stewart AK, Menck HR. The national cancer database report on treatment patterns for hepatocellular carcinomas: Improved survival of surgically resected patients,1985-1996. Cancer, 2000,88:912-920
[4] Gannon CJ, Curley SA. The role of focal liver ablation in the treatment of unresectable primary and secondary malignant liver tumors. Semin Radiat Oncol, 2005, 15:265-272
[5] Castells A, Brujx J, Bru C, et al. Treatmentment of smallhepato-cellular carcinoma in cirrhotic patients:acohort study comparing surgical resection and percutaneous ethand jection. Hepatology, 1993, 18:1121-1126
[6] Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. J Hepatol, 2001, 35:421-430
[7] Dong BW, Zhang J, Liang P, et al. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. Int J Hyperthermia, 2003, 19(2): 119-33
[8] Zhang J, Dong B, Liang P, et al. Significance of changes in local immunity in patients with hepatocellular carcinoma after percutaneous microwave coagulation therapy. Chin Med J(Engl), 2002,115(9):1367-1371
[9] Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonocally guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer, 1994, 74(3) :817-825
[10] Liang JD, Yang PM, Huang GT, et al. Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma. J Formos Med Assoc, 2004, 103(12): 908-13
[11] Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol, 2003, 9(9): 1885-91
[12] Chen MS, Li JQ, Zheng Y, et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Ann Surg, 2006,243: 321-328
[13] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology, 2003, 37:429-442
[14] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology, 2004,40:1352-1360
[15] Lu MD, Yin XY, Xie XY, et al. Percutaneous thermal ablation for recurrent hepatocellular carcinoma after hepatectomy. Br J Surg, 2005, 92(11): 1393-1398
[16] Seki T, Wakabayashi M, Nakagawa T, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma, comparison with percutaneous ethanol injecton therapy. Cancer, 1999,85 (8):1694-1702
[17] Isozaki T, Numata K, Kiba T, et al. Differential Diagnosis of Hepatic Tumors by Using Contrast Enhancement Patterns at US. Radiology, 2003, 229(12): 798-805
[18] Herbay AV, Vogt C, Willers R, et al. Real-time Imaging With the Sonographic Contrast Agent SonoVue: Differentiation Between Benign and Malignant Hepatic Lesions. Ultrasound Med, 2004,23(12):1557-1568
[19] Albrecht T, Blomley M, Burns P, et al. Improved detection of hepatic metastases with pulse inversion US during the liver specific phase of SH USO8A : multicenter study[J].Radiology, 2003,227(2):361-370
[20] 陈敏华，杨薇，严昆等．超声造影对确定肝癌射频消融范围及治疗策略的应用价值．中华超声影像学杂志，2006，15(3)：193-197
[21] Okudu K. Hepatocellar carcinoma:clinicopathological aspects. J Gastroentrol Hepatol, 1997,12(9-10):S314
[22] Liu DM, Salem R, Bui JT, et al. Angiographic considerations in patients undergoing liver directed therapy. J Vasc Interv Radiol 2005; 6:911-935
[23] Song SY, Chung JW, Lim HG, et al. Nonhepatic Arteries Originating from the Hepatic Arteries: Angiographic Analysis in 250 Patients. Journal of Vascular & Interventional Radiology, 2006,17(3):461-469
[24] Imanura M, Shiratori Y, Shiina S, et al. Power Doppler sonography for hepatocellularcarcinomaLfactors affecting power Doppler signals of the tumor. Eur J Radiol, 1998,27:S157-160
[25] Madjar H, Prompler HJ, Del Favero V, et al. A new Doppler signal enhancing agent for flow assessment in breast lesions.European Journal of Ultrasound, 2000,12:123-130
[26] Quaiao E,Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material[J].Acad Radiol, 2003, 10(7):739-750
[27] Quaia E,Caliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble-contrast agent:diagnostic performance and confidence. Radiology, 2004, 232(2):420-430
[28] Okabe M. Patho-morphological studies on hepatocellular carcinoma:a study on a mechanism of capsule formation and septum formation of tumor nodule (Japanese). Acta Hepatol Jpn, 1979, 20:144 - 56
[29] Lirraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology, 2000, 214:761-768
[30] Livraghi T, Meloni F, Morabito A, et al. Multimodal image-guide tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl, 2004, 10 (suppll):S98 - S106
[31] Liang JD, Yang PM, Huang GT, et al. Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma. J Formos Med Assoc, 2004, 103(12): 908-913
[32] Horigome H, Nomura T, Saso K, et al. Standards for selecting percutaneous ethanol injection therapy or percutaneous microwave coagulation therapy for solitary small hepatocellular carcinoma: consideration of local recurrence. Am J Gastroenterol, 1999, 94: 1914 -1917
[33] Livraghi T, Goldberg SN, Lazzaroni S, et al. Radiofrequency ablation vs. ethanol injection in the treatment of small hepatocellular carcinoma. Radiology, 1999, 210:655 - 661
[34] De Baere T,Bessoud B,Dromain C,et al. Percutaneous radio- frequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol, 2002,178:53-59
[35] Washburn W. K, Dodd G.D Kohlmeier R.E et al. Radiofrequency tissue ablation: effect of hepatic blood flow occlusion on thermal injuries produced in cirrhotic livers[J].Annals of surgical oncology, 2003,10(7):773-777
[36] Bruix J, Sherman M, Llovet ]M, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol, 2001,35:421
[37] Liang JD, Yang PM, Huang GT, et al. Percutaneous microwave coagulation therapy under ultrasound guidance for small hepatocellular carcinoma. J Formos Med Assoc, 2004, 103(12):908-913
[38] Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol, 2003, 9(9): 1885-1891
[39] Goldberg SN, Kruskal JB, Oliver BS, et al. Percutaneous tumor ablation:increased coagulation by combining radio-frequency ablation and ethanol instillation in a rat breast tumor model. Radiology, 2000, 217: 827-831
[40] Clark Timothy W.I, Soulen MC. Chemical ablation of hepatocellular carcinoma. J Vasc Interv Radiol, 2002,13:S245-S252
[41] Seki T, Tamai T, Nakagawa ZT, et al. Combination therapy with transcatherter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer, 2000, 89:1245-1251
[42] 姜晓龙，孙巍，贾奇志，等．超声引导微波热凝固结合肝动脉栓塞化疗治疗肝癌．中华超声影像学杂志，2002，11：13-15
[43] Shibata T, Murakami T, Ogata N. Percutaneous microwave coagulation therapy for patients with primary and metastatic hepatic tumors during interruption of hepatic blood flow. Cancer, 2000,88:302-311
[44] Murakami T, Shibata T, Inoue Y, et al. Percutaneous microwave tumor coagulation for hepatocellular carcinomas with interruption of segmental hepatic blood flow. J Vasc Interv Radiol, 2002,13:185-191
[45] Kojiro M. Focus on dysplastic nodules and early hepatocellular carcinoma:an eastern point of view. Liver Transpl, 2004,10:S3-S8
[46] Dromain C, de Baere T, Elias D, et al. Detection and characterisation of liver metastases. Eur Radiol, 2004,14 Supp18:25-33
[47] Numata K, Tanaka K, Kiba T, et al. Contrast-enhanced, wide-band harmonic gray scale imaging of hepatocellular carcinoma: correlation with helical computed tomographic findings. J Ultrasound Med, 2001,20:89
[48] Quaiao E, Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material[J].Acad Radiol, 2003,10(7):739-750
[49] D'Onofrio M, Rozzanigo U, Masinielli BM, et al. Hypoechoic focal liver lesions: characterization with contrastenhanced ultrasonography. J Clin Ultrasound, 2005, 33(4): 164-172
[50] Lencioni R, Cioni D, Bartolozzi C. Tissue harmonic and contrastspecific imaging: back to gray scale in ultrasound. Eur Radiol, 2002, 12:151-165
[51] Quaia E, Calliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast specific US modes and a sulfur hexafluoride - filled microbubble contrast agent:diagnostic performance and confidence. Radiology, 2004,232:420 - 430
[52] Dietrich C F, Ignee A, Trojan J, et al. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut, 2004,53:401-405
[53] Maruyama H, Matsutani S, Saisho H, et al. Real-time blood-pool images of contrast enhanced ultrasound with definity in the detection of tumor nodules in the liver. Br J Radiol, 2005,78:512-518
[54] Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatmentwith radiofrequency ablation versus ethanol inject ion[J].Radiology, 1999,210(3):655-661
[55] Vallone P, Gallipoli A, Izzo F, et al. Local ablation procedures in primary liver tumors: Levovist US versus spiral CT to evaluate therapeutic results. Anticancer Res, 2003,23(6D):5075-5079
[56] 裴小青，李安华，韩峰等．超声造影成像对TACE综合治疗肝癌疗效的评判价值与螺旋CT对比分析．中国超声医学杂志，2005，21(10)：764-766
[1]Albrecht T, Mattrey RF. Tumar imaging with ultrasound contrast. In:Thomsen HS, Muller RN, Mattrey RF(eds) Trends in contrast media. Medical radiology:diagnostic imaging and radiation oncology series. Springer, Berlin Heidelberg New York, 1999,pp367-382
[2] Quaiao E, Bertolotto M, Calderan L, et al. US characterization of focal hepatic lesions with intermittent high-acoustic-power mode and contrast material[J]. Acad Radiol, 2003,10(7):739-750
[3] Ignee A, Weiper D, Schuessler G, et al. Sonographic characterisation of hepatocellular carcinoma at time of diagnosis. Z-Gastroenterol, 2005, 43(3): 289-294
[4] Borden MA, Kruse DE, Caskey CF, et al. Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction. IEEE Trans Ultrason Ferroelectr Freq Control, 2005, 52(11): 1992-2002
[5] Sonoda S,Tachibana K, Uchino E, et al. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles.Invest Ophthalmol Vis Sci, 2006, 47(2): 558-564
[6] Gramiak R, Shah PM. Echocardiography of the aortic root. Invest Radiol, 1968,3:356-366
[7] Schnerder M, Arditi M, BarrAu M B, et al.BRI:a new ultasonographic contrast agent based on sulfur hexafluoride-filled microbubbles[J]. Invest adiol, 1995,30(8) :451-457
[8] Bauer A, Blomey M, Leen E, et al. Liver-specific imaging with SHU563A:diagnostic potential of a new class of ultrasound contrast media. Eur Radial, 1999, 9(supple 3):S349-352
[9] Correas JM, Bridal L, Lesarre A, et al. Ultrasound contrast agent: properties, principles of action, tolerance and artifacts. Eur Radiol, 2001,11:1316-1328
[10] Schnerder M. SonoVue, a new ultrasound contrast agent. Eur Radiol, 1999, 9 (suppl 3):347-348
[11] Correas J-M, Bridal L, Lesavre A, Mejean A, et al. Ultrasound contrast agents: properties,principles of action, tolerance, and artifacts. Eur Radiol, 2001,11:1316-1328
[12] Bokor D, Chambers JB, Rees PJ, et al. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease. Invest Radiol, 2001, 36:104-109
[13] Kaps M, Seidel G,Bokor D,et al. Safety and ultrasound enhancing potentials of a new sulfur hexafluoride-containing agent in the cerebral circulation. J Neuroimaging, 1999,9:150-154
[14] Leen E, Angerson WJ, Yarmenitis, et al. Multi-centre clinical study evaluating the efficacy of SonoVue (BRI), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur Radiol, 2002, 41:200-206
[15] Madjar H, Prompler HJ, Del Favero V, et al.A new Doppler signal enhancing agent for flow assessment in breast lesions. European Journal of Ultrasound, 2000, 12:123-130
[16] Von Bibra H, Erne P, Bokor D, et al. SonoVue for left heart Doppler contrast enhancement:a phase II two-center study. Presented at the World Congress of Cardiology;RIO de Janeiro, Brazil,1998,4: 26-30
[17] Bogdahn U, Hoelscher T, Rosin L, et al. Contrast-enhanced trans-cranial and extracranial Duplex sonography:preliminary results of a multicenter phase II/III study with SonoVue. Echocardigraphy, 1999, 16 (2):761-766
[18] Dalla Palma L, Bertolotto M. Introduction to ultrasound contrast agent:physics overview. Eur Radiol, 1999, 9(Suppl 3):338-342
[19] De Jong N, Cornet R, Lancee CT. Higher harmonics of vibrating gas filled microspheres. Part one:Simulations. Ultrsonics, 1994,32:447-453
[20] Forsberg F, Goldberg BB, Liu JB, et al. Tissue-specific US contrast agent for evaluation of hepatic and splenic parenchyma. Radiology, 1999,210:125-132
[21] Barr R. Seeking consensus:contrast ultrasound in radiology. Eur J Radiol, 2002, 41:207-216
[22] Correas JM, Bridal L, Lesarre A, et al. Ultrasound contrast agent:properties, principles of action to lerance and artifacts. Eur Radiol, 2001,11:1316-1328
[23] Barr R. Seeking consensus:contrast ultrasound in radiology. Eur J Radiol, 2002,41:207-216
[24] Burns PN. Harmonic imaging with ultrasound contrast agents. Clinic Radiol, 1996,51:S50-S55
[25] Frinking PJA, Bouakaz A, Kirkhorn J, et al. Ultrasound contrast imaging:current and new potential. Ultrasound Med Biol, 2000,26(6): 965-975
[26] Hope Simpson D, Chin CT, Burns. Pulse inversion Doppler:a new method for detecting non-linear echoes from microbubble contrast agents. Frequency Control, 1999,46:372-382
[27] Verbeek XA, Ledoux LA, Willigers JM, et al. Experimental investigation of the pulse inversion technique for imaging ultrasound contrast imaging agents[J]. Jacoust Soc Am, 2000,107(4):2281-2290.
[28] Peter JA, Bouakaz A, Kirkhorn J, et al. Ultasound Contrast imaging: current and new potential methods. Ultrasound Med Riol, 2000, 26(6): 965-975
[29] Leene. Ultasound contrast harmonic imaging of abdominal organs. Sermin Ultrasound CT MRI, 2001,22(1):11-24
[30] Gaiani S, Celli N, Piscaglia F, et al. Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. J Hepatol, 2004,41(3):421-426
[31] Lencioni R, Cioni D, Donati F, et al. SonoVue-enhanced C3-mode US imaging in the detection and characterization of focal liver lesions:a pilot clinical study. Eur Radiol, 2001,9:C4
[32] Luo BM, Wen YL, YangHY, et al. Differentiation between malignant and benign nodules in the liver: use of contrast C3-MODE technology. World J Gastroenterol, 2005,11(16):2402-2407
[33] Lee JY, Choi BI, Han JK, et al. Improved sonographic imaging of hepatic hemangioma with MR imaging. Ultrasound Med Biol, 2002,3:287-295.
[34] 陆兆龄，陈常佩．新型超声对比造影剂和成像技术在心脏以外领域中的应用[J]．中国医学影像技术，2001，17(9)：866-869
[35] Cosgrove DO, blomley MJK, Eckersley RJ, et al. Innovative contrast specific imaging with ultrasound[J].Electromedica, 2002,70:147-150
[36] Phillips RJ, Contrast pulse sequences(CPS):imaging nonlinear microbubbles[J]. IEEE Ultrasonic Symposium, 2001, 1739-1745
[37] Choi BI, Kim TY, Han JK, et al. Vascularity of hepatocellular carcinoma:assessment with contrast-enhanced second-harmonic versus conventional power Doppler US. Radiology, 2000,214:381-386
[38] 王威琪，汪源源，余建国．医学超声中谐波技术的有关问题．世界医疗器械，1999，5(10)：30-34
[39] Shankar PM, Dala Krishna, et al. Advantages of subharmonic over second hamonics backscatter for contrast-to-tissue echo enhancement. Ultrasound Med Biol,1998,24:395-399
[40] Burns PN, Wilson SR, Kahlilik, Contrast-enhanced pulse inversion imaging of the liver with aperflurocarborn agent:protocol for the differential diagnosis of focal lesion. Radiology, 2000,217:458
[41] Atbrecht T, Urbank A, Mahler M, et al. Prolongation and optimization of Doppler enhancement with amicrobubble US contrast agent by using continuous infusion:preliminary experience. Radiology, 1998,207:339-347.
[42] Spinazzi A. Emerging clinical applications for contrast-enhanced ultrasonography. Eur Radiol, 2OOl, 11(Suppl 3):E7-E12
[43] Albrecht T, Hoffmann CW, Schettler S, et al. Improved detection of liver metastases with phase inversion imaging during the liver-specific phase of the ultrasound contrast agent Levovist. Eur Radiol, 1999,9(Suppl 3):388
[44] Kim TK, Choi .BI, Han JK, et al. Hepatic Tumors:contrast agentenhancement patterns with pulse-inversion harmonic US. Radiology,2000,216:411-417
[45] Bertolotto M, Dalla Palma L, Quaia E, et al. Characterization of unifocal liver lesions with pulse inverson harmonic imaging after Levovist injection:preliminary results. Eur Radiol, 2000,10:1369-1370
[46] Youk JH, Kim CS, Lee JM. Contrast-enhanced agent detection imaging:value in the characterization of focal hepatic lesions. J Ultrasound Med, 2003,22(9):897-910
[47] Quaia E, Caliada F, Bertolotto M, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble-contrast agent:diagnostic performance and confidence. Radiology, 2004, 232 (2):420-430
[48] Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographic, 2004, 23(4):921-935
[49] Bauer A,Schlief R, Zomack M, et al. Acoustically stimulated microbubbles in diagnostic ultrasound:properties and implications for diagnostic use. In:Nanda N, Schlief R, Goldberg BB(eds)Advances in echo imaging using contrast enhancement, 2nd edn. Kluwer, Lancaster, England, 1997,pp9-19
[50] Hauff P, Fritzsch T, Reinhardt M, et al. Delineation of experimental liver tumors in rabbits by anew ultrasound contrast agent and stimulated acoustic emission. Invest Radiol, 1997, 32:94-99
[51] Bauer A, Blomley MJK, Leen E, et al. Liver specific imaging with SHU563 A:diagnostic potential of a new class of ultrasound contrast media. Eur Radiol, 1999, 9:S349-S352
[52] Takayasu K,Moriyama Y, Mzkuuchim. The diagnosis of smallhepato-cellular carcinomas:efficacy of various imaging procedure in 100 patients. Am J Roentgenol, 1990,55:49-54
[53] Dodii G, Miller W, Baron R. Detection of malignant tumors in endstage cirrhotic livers:efficacy of sonography as a screening technique. Am J Roentgenol, 1992,159:727-733
[54] Wernecke K, Rummency E, Bongartz G, et al. Detection of hepatic masses in patients with carcinoma:comparative sensitivities of sonography, CT,and MR imaging. AJR, 1991,157:731-739
[55] Kinkel K, lu Y, Both M, et al.Detection of hepatic metastases from cancer of the gastrointestinal tract by using noninvasive imaging methods(US, CT.Hrimaging, PET):a meta-anaysis. Radiology, 2002, 224:748-756
[56] Albrecht T, Hoffmann CW, Schmitz SA, et al. Phase-inversion sonography during the liver-specific late phase of contrast enhancement:improved detection of liver metastases. AJR. 176:1191-1198
[57] Palma LD. D iagnostic imaging and interventional therapy of hepatocellular carcinoma. Br J Radiol, 1998, 71(848):808
[58] Itoh Y, A kamatsu K. Relationships between echo level and histologic characteristics in small hepatocellular carcinomas. J Clin Ultrasound, 1998, 26(6):295
[59] Iwasaki M, Furuse J , Yosh inoM , et al. Sonograph ic appearances of small hepatic nodules without tumor stain on contrast-enhanced computed tomography and angiography. J Clin Ultrasound, 1998, 26 (6) : 303
[60] Hann LE, Bach AM, Cramer LD, et al. Hepatic sonography :comparison of tissue harmonic and standard songraphy techniques. AJR. 173:201-206
[61] Tanaka S, Oshikawa O, Sasaki T, et al. Evaluation of tissue harmonic imaging for diagnosis of focal liver lesions. Ultrasound Med Biol, 2000, 26:183-187
[62] Harvey CJ, Albrecht T. Ultrasound of focal liver hepatic lesions. Eur Radiol, 2001,11:1578-1593
[63] Koda M, Matsunage Y, Ueki M, et al. Qualitative assessment of tumor vascularity in hepatocellular carcinoma by contrast-enhanced coded ultrasound:comparison with arterial phase of dynamic CT and conventional color/power Doppler ultrasound[J]. Eur adiol, 2004,14:1100- 1108
[64] Nicolau C, Catala V, VilanaR, et al . Evaluation of hepatocellular carcinoma using SonoVue, a second generation ultrasound contrast agent : correlation with cellular differentiation[J].Eur Radiol, 2004,14 (6):1092-1099
[65] Strobel D, Kleinecke C, Hansler J, et al. Contrast-enhanced sonography for the characterisation of hepatocellular carcinomas—-correlation with histological differentiation. Ultraschall Med, 2005, 26(4): 270-276
[66] Quaia E, Calliada F, Bertolotto M, et al. Characterization of focalliver lesions with contrast-specific US modes and a sulfur hexafluo-ride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology, 2004, 232(2):420-430
[67] Brannigan M, Burns PN, Wilson SR. Blood flow patterns in focal liver lesions at microbubble-enhanced US. Radiographics, 2004, 24(4):921-935.
[68] Solbiati L, Martegani A, Leen E, et al. Contrast-enhanced ultrasound of liver diseases. Milan : Springer, 2003, 44-87
[69] Youk JH, Kim CS, Lee JM. Contrast enhanced agent detection imaging[J]. J Ultrasound Med, 2003, 22(9):897-910
[70] Kim SH, Lee JM, Lee JM, et al. Value of contrast-enhanced sonography for the characterization of focal hepatic lesions in patients with diffuse liver disease: receiver operating characteristic analysis. AJR Am J Roentgenol, 2005,184(4):1077-1084
[71] von Herbay A, Vogt C, Willers R, et al. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. J Ultrasound Med, 2004,23(12):1557-1568
[72] Isozaki T , Numata K, Kiba T , et al. Differential diagnosis of hepatic tumors by using contrast enhancement patterns at US. Radiology, 2003, 229(3):798-805
[73] Rabenandrasana HA, Furukawa A, Furuichi K, et al. Comparison between tissue harmonic imaging and liver-specific late-phase contrast-enhanced pulse-inversion imaging in the detection of hepatocellular carcinoma and liver metastasis. Radiat Med, 2004,22(2): 90-97
[74] Diet rich CF, Ignee A, Trojan J, et al . Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU508A[J]. Gut,2004, 53(3):401-405
[75] Bernatik T, Becker D, Neureiter D, et al. Hepatic transit time of an echo enhancer: an indicator of metastatic spread to the liver. Eur J Gastroenterol Hepatol, 2004,16(3):313-317
[76] Wen YL, Kudo M, Zheng RQ, et al. Characterization of hepatic tumors:value of contrast-enhanced code phase-inversion harmonic angio[J]. AJR, 2004,182:1019-1026
[77] Dill-Macky MJ , Burns PN , Khalili K, et al . Focal Hepatic Masses: Enhancement Patterns with SHU508A and Pulse Inversion US[J]. Radiology, 2002, 222(1):95-102
[78] Uggowitzer MM, Kugler C, Mischinger HJ, et al. Echo - enhanced Doppler sonography of focal nodular hyperplasia of the liver [J].J Ultrasound Med, 1999, 18:445-451
[79] Solbiati L, Martegani A , Leen E , et al . Contrast-enhanced ultrasound of liver dieases[M]. Italia Milano: Springer-Ver-lag, 2003, 37-93
[80] Solbiati L , Martegani A , Leen E , et al . Contrast-enhanced ultrasound of liverdieases[M]. Italia Milano: Springer-Ver-lag, 2003, 37-93
[81] Solbiati L, Cova L, Lerace T, et al. The importance of arterial phase imaging for wadeband harmonic sonography for the characteriza of focal lesions in level cirrhosis using a second generation contrast agent. Radiology, 2000, 217:305
[82] Nishiharu T, Yamashita Y, Arakawa A, et al. Sonographic comparison of intraarterial C02 and helium microbubbles for detection of hepatocellular carcinoma: prelim inary observations. Radiology, 1998,206 (3): 767
[83] Dalla PL, Bertolotto M, Quaia E, et al. Detection of liver metastases with pulse inversion harmonic imaging:preliminary results. Eur Radiol, 1999,9(suppl 3):382-387
[84] Harvey CJ, Blomley MJ, Eckersley RJ, et al. Hepatic malignancies: improved detection with pulse-inversion US in late phase of enhancement with SHU 508-early experience. Radiology, 2000, 216:903-908
[85] Kim TK, Choi BI, Hong H, et al. Improved imaging of hepatic metastases with delayed pulse inversion harmonic imaging using a contrast SHU508A:preliminary study. Ultrasound Med Biol, 2000, 26:1439-1444
[86] Albrecht T, Hoffmann CW, Schettler S, et al. B-mode enhancement at phase-inversion US with air-based microbubble contrast agent:initial experience in humans. Radiology, 2000, 216:273-278
[87] Albrecht T, Blomley M, Golgberg B, et al. Detection of focal liver lesion with the new RES-specific echo contrast agent NC100100:results of an explorative multicenter study.Ultraschall Med,2000,21(suppl):24
[88] Oldenburg A, Hohmann J, Foert E, et al. Detection of hepatic metastases with low MI real time contrast enhanced sonography and SonoVue. Ultraschall Med, 2005,26(4):277-284
[89] Albrecht T, Blomley M, Burns P, et al. Improved detection of hepatic metastases with pulse inversion US during the liver specific phase of SH U508A : multicenter study[J]. Radiology, 2003, 227(2):361-370
[90] Castells A, Brujx J, Bru C, et al. Treatmentment of small hepatocellular carcinoma in cirrhotic patients:acohort study comparing surgicalresection and percutaneous ethand jection. Hepatology, 1993, 18: 1121-1126
[91] Nagao T, Inoue S, Yoshimi F, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg, 1990, 211:28 - 33
[92] Belghiti J, Panis Y, Farges O, et al. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg, 1991, 214:111-114
[93] Uchida H, Ohishi H, Matsui N, et al. Trancatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol,1990,13:140-145
[94] Livraghi T, Giorgio A, Marin G. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology, 1995,197:101 - 108
[95] Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer, 1994, 74:817 - 825
[96] Rossi S, Di Stasi M, Buscarini E, et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am J Roentgenol, 1996,167:759 - 768
[97] Amin Z, Donald JJ, Masters A, et al. Hepatic metastases: 7interstitial laser photocoagulation with real-time US monitoring and dynamic CT evaluation of treatment. Radiology, 1993,187:339 - 347
[98] Skjoldbye B, Pedersen MH, Struckmann J, Burcharth F, et al. Improved detection and biopsy of solid liver lesions using pulse-inversion ultrasound scanning and contrast agent infusion [J].Ultrasound Med & Biol,2002, 28 (4):439-444
[99] Oi H. Liver intervention. Nippon Igaku Hoshasen Gakkai Zasshi, 2000,60:826-832
[100] De Baere T, Bessoud B, Dromain C, et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol, 2002, 178:53-59
[101] Hsu HC, Wei TC, Tsang YM, et al. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepaticarterial embolization. Cancer, 1986, 57:1184-1191
[102] Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC).Eur Radiol, 2005,14:1-9
[103] Minami Y, Kudo M, Kawasaki T, et al. Treatment of hepatocellular carcinoma with percutaneous radiofrequency ablation: usefulness of contrast harmonic sonography for lesions poorly defined with B-mode sonography. AJR Am J Roentgenol, 2004,183(1):153-156
[104] Shimizu M, Iijima H, Horibe T, et al. Usefulness of contrast-enhanced ultrasonography with a new contrast mode, Agent Detection Imaging, in evaluating therapeutic response in hepatocellular carcinoma treated with radio-frequency ablation therapy. Hepatol Res,2004, 29 (4):235-242
[105] Vallone P, Gallipoli A, Izzo F, et al. Local ablation procedures in primary liver tumors: Levovist US versus spiral CTto evaluate therapeutic results. Anticancer Res, 2003, 23(6D):5075-5079
[106] Solbiati L, Lerace T,Tonolini M, et al. Guidance and control of percutaneous treatments with contrast-enhanced ultrasound[J]. Eur adiol, 2003,13(Suppl3):N87-N90
[107] Numata K, Isozaki T,Ozawa Y, et al. Percutaneous ablation therapy guided by contrast-enhanced sonography for patients with hepatocellular carcinoma[J].AJR,2003,180(1):143-149
[108] Solbiati L, Goldberg SN, Dellanoce M, et al. Radio-frequency ablation of hepatic metastases:postprocedural assessment with a US microbuble contrast agent-early experience. Radiology, 1999, 211(3): 643-649
[109] Zhou X, Strobel D, Haensler J, et al. Hepatic transit time: indicator of the therapeutic response to radiofrequency ablation of liver tumours.Br J Radiol, 2005,78(929):433-436
[110] Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet,1999,353 (9164):1579-1583
[111] Tamano M. Yoneda M. Kojima K,et al. Evaluation of esophageal varices using contrast-enhanced coded harmonic ultrasonography. Journal of Gastroenterology & Hepatology, 2004,19(5):572-575
[112] Michelle L, Therese M. The potential role of ultrasound contrast agents in the liver[J].Applied Radiology, 1997,26:13-18
[113] Lawrie A, Brisken AF, Francis SE, etal. Microbubble-enchanced ultrasound for vascular delivery. Gene Ther, 2000,7:2023-2027
[114] Unger EC , Matsunaga TO , McCreery TP , et al. Therapeutic applications of microbubbles. Eur J Radiol, 2002,42:160-168
[115] Huai L, Birnbaum Y, Fishbein TM, et al. Enhancement of thrombolysis in vivo without skin and soft tissue damage by transcutaneous ultrasound. Thromb Res, 1998,89:171-177
[116] 吴巍，宁新宝，姜藻，等．低功率超声辐射Levovist试剂致家兔肝脏微血管栓塞的研究．东南大学学报(自然科学版)，2003，33：399-402
[1] Duvoux C.Epidemiology and diagnosis of HCC in cirrhosis. Ann Chir, 1998, 52:511-7
[2] Bruix J, Castells A, Bru C. Caracteristicas clinicas y pronostico del carcinoma hepatocelular. Existen diferencias geograficas? Gastroenterol Hepatol,1991,14: 520-524
[3] Yoo HY,Patt CH,Geschwind JF,et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the united States between 1988 and2001: 5-year survival has improved significantly with time. J Clin Oncol, 2003,21: 4329-4235
[4] Goldstein HM, Wallace S, Anderson JH,et al. Transcatheter occlusion of abdominal tumors. Radiology, 1976, 120:539-545
[5] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology,2003, 37:429-442
[6] Bhattacharya S, Davidson B, Dhillon AP. Blood supply of early hepatocellular carcinoma. Semin Liver Dis, 1995,15:390-401
[7] Cohen SE, Safadi R, Verstandig A, et al. Liver-spleen infarcts following transcatheter chemoembolization: a case report and review of the literature on adverse effects. Dig Dis Sci,1997, 42: 938-943
[8] Llovet JM, Real MI, Montana X, et al. Aterial embolisation or chemo-embolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet,2002,359:1734-1739.
[9] Bronowick JD,Vetter D,Dumas F,et al.Transcatheter oily chemoembolization for hepatocellular carcinoma, cancer, 1994,74:16
[10] Takayasu K, Shima Y, Muramatsu Y, et al. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology, 1987,162:345-51
[11] Matsui O, Kadoya M, Yoshikawa J, et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate.Cancer Chemother Pharmacol, 1994,33(suppl):84-88
[12] Raoul JL, Heresbach D, Bretagne JF, et al. Chemoembolization of hepatocellular carcinomas. Cancer, 1992,70:585-590
[13] Fan J, Tang ZY, Yu Y, et al. Improved survival with resection after trancatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma.Dig Surg 1998,15:674-678
[14] Kanai T,Hirohashi S,Upton MP,et al. Pathology of small hepatocellular carcinoma. Aproposal for a new gross classification.Cancer,1987, 60(4):810-819
[15] Choi BI,Kim HC,Han JK,et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings.Radiology,1992,182(3):709-713.
[16] Nishimura Y,Uhida H,Guo Q,et al.J Jpan Soc Cancer Ther, 1991,26:2279-2289
[17] Matsui O, Kadoya M, Yoshikawa J, et al. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol, 1994,33(suppl):84-88
[18] Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan.Hepatology,2000, 32:1224-1229
[19] Livraghi T, Giorgio A, Marin G, et al.Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology, 1995, 197:101-108
[20] Lencioni R, Pinto F, Armillotta N, et al.Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol, 1997,7:514-519
[21] Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jp J Clin Oncol, 1998, 28:604-608
[22] Orlando A, D'Antoni A, Camma C. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection: a validated prognostic model. Am J Gastroenterol,2000,95:2921-2927
[23] Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. Hepatology,2000,32:1224-1229
[24] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology,2004, 40: 1352-1360
[25] Livraghi T, Meloni F, Morabito A, et al. Multimodal image-guide tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl,2004,10(suppl1): S98-S106
[26] Shiina S, Tagawa K, Unuma T, et al.Percutaneous ethanol injection therapy for hepatocellular carcinoma: a histopathologic study.Cancer, 1991,68:1524-1530
[27] Livraghi T, Lazzaroni S, Pellicano S,et al. Percutaneous ethanol injection of hepatic tumors: single-session therapy with general anesthesia. AJR Am J Roentgenol,1993,161:1065-1069
[28] Livraghi T,Benedini V,Lazzaroni S,et al.Long-term results of single session percutaneous ethanol injection in patients with large hepatocellar carcinoma.Cancer, 1999,83:48-57
[29] Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet, 2003, 362:1907-1917
[30] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology,2004,40: 1352— 1360
[31] Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology, 1998,27:67-72
[32] Sala M, Llovet JM, Vilana R, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology,2004,40: 1352- 1360
[33] Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image-guide tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl, 2004,10 (suppl1): S98-S106
[34] Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jp J Clin Oncol, 1998,28:604-608
[35] Daniele B,De Sio I, Izzo F,et al. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. J Clin Gastroenterol, 2003, 36(1): 63-7
[36] Mazzanti R,Arena U,Pantaleo P,et al. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience. Canadian Journal of Gastroenterology, 2004,18(10):611-618
[37] Lin LW, Lin XY, He YM,et al. Experimental and clinical assessment of percutaneous hepatic quantified ethanol injection in treatment of hepatic carcinoma. World J Gastroenterol, 2004,10(21):3112-3117
[38] Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of longterm results after percutaneous ethanol injection therapy and surgical resection.Hepatology, 2001, 34:707-713
[39] Ishii H, Okada S, Nose H, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection.Cancer, 1996, 77:1792-1796
[40] Khan KN, Yatsuhashi H, Yamasaki K,et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol,2000, 32:269-278
[41] Tanaka K,Nakamura S,Numata K,et al. Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization.Radiology, 1992,185(2):457-60
[42] Mc Gahan JP, Browning PD, Brock JM, et al. Hepatic ablation using radiofrequency electrocautery.Invest Radiol, 1990,25:267-270
[43] Rossi S, Fornari F, Paties C, et al.Thermal lesions induced by 480 kHz localized current field in guinea pig and in pig livers. Tumori, 1990,76:54-57
[44] Rossi S,Fornari F,Buscarini L.Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma.J Intervent Radiol, 1993,8:97-103
[45] Dickson JA, Calderwood SK. Temperature range and selective sensitivity of tumors to hyperthermia: a critical review. Ann NY Acad Sci, 1980,335:180-205
[46] Hill RP, Hunt JW. Hyperthermia. In: Tannock IF, Hill RP, eds.The Basic Science of Oncology. New York: Pergamon Press, 1987,337-357
[47] Haines DE, Watson DD, Halperin C. Characteristics of heat transfer and determination of temperature gradient and viability threshold during radiofrequency fulguration of isolated perfused canine right ventricle. Circulation, 1987,76:278-283
[48] Grundfest WS, Litvack FI, Doyle DL,et al. Laser-tissue interactions: considerations for cardiovascular applications. In:White RA, Grundfest WS, eds. Lasers in Cardiovascular Disease. Chicago: Yearbook Medical Publishers, 1987:32-43
[49] McGahan JP, Brock JM, Tesluk H, et al. Hepatic ablation with use of radiofrequency electrocautery in the animal model. J Vasc Interv Radiol, 1992,3:291-297
[50] 郑云，李锦清，陈敏山，等．气冷微波固化与传统微波固化杆温对治疗效应影响的比较研究．癌症，2004，23(11s)：1477—1481
[51] 广火田成也，安武晃一．肝癌对经皮的治疗—PEIT，MCT，RFA[J]．结合消化器，2002，7(5)：12-16
[52] Curley SA, Izzo ,F, Ellis L, et al. Radiofrequency ablation of malignant liver tumors in 304 patients. Proc Am Soc Clin Oncol,2000,19:248a
[53] Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Kadiat Oncol Biol Phys, 1979,5:235-242
[54] Curley SA ,Izzo F ,Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 cirrhotic patients. Ann Surg,2000,232:381-391
[55] Leveillee RJ, Hoey MF.Radiofrequency interstitial tissue ablation:wet electrode. J Endourol, 2003,17:563-577
[56] Rossi S, Buscarini E, Garbagnati F, et al.Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. Am J oentgenol,1998,170: 1015-1022
[57] Gazelle GS, Goldberg SN, Solbiati L, et al.Tumor ablation with radio-frequency energy. Radiology, 2000,217:633-646
[58] Yamasaki T, Kurokawa F, Shirahashi H, et al. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow: comparison with standard percutaneous radiofrequency ablation therapy. Cancer, 2002,95:2353-2360
[59] Ikeda M, O kada S, U eno H, et al. Radiofrequency ablation and percutaeous ethanol injection in patients with small hepatocellualr carcinoma: a comparative study [J]. Jpn J Clin O ncol, 2001,31 (7):322-326
[60] Curdy SA, lzzo F, Ellis LM, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies, result in 123 patients [J]. Ann Surg, 1999,230(1): 1-8
[61] Liu LX, Jiang HC, Piao DX, et al. Radiofrequence ablation of liver cancers [J]. World J Gastroenterol,2002,8(3):393- 399
[62] Curely SA. Radiofrequency ablation of malignant liver tumors[J].Oncologist, 2001, 6(1):14-23
[63] Solbiati L , Golderg SN, lerace T, et al. Hepatic metastases: percutaneous radiofrequency ablation with cooled-tip electrodes [J]. Radiology, 1997,205(2): 367-373
[64] MachiJ, Uchida S, Sumida K, et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparo scopic and open surgical approaches [J]. J Gastrointest Surg,2001,5(5): 477-489
[65] Livraghi T, Goldberg SN, Lazzaroni S, et al. Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol inject ion [J].Radiology, 1999, 210(3):655-661
[66] Tamai F, Furuse J , Maru Y, et al. Intrahepatic pseudoaneurysm: a complication following radiofrequency ablation therapy for hepatocellular carcinoma [J]. Eur J Radio 1, 2002,44(1):40-43
[67] Wong SL , Edwards MJ, Chao C, et al.Radiofrequency ablation for unresectable hepatic tumors [J]. Am J Surg, 2001,182 (2): 552-557
[68] Ng KK, Lam CM, POOh RT, et al. Portal vein thrombosis after radiofrequency ablation for recurrent hepatocellular carcinoma [J]. Asian J Surg,2003, 26 (1):50-53
[69] Livraghi T, Goldberg SN , Lazzaroni S, et al. hepatocellular carcinoma: radio-frequency ablation of medium and large lesions [J].Radiology,2000,214(3): 761-768
[70] Cutely SA, Izzo F,Delrio P, et al. Radiofrequency ablation of urtresectable primary and metastatic hepatic malignancies: result in 123 patients. Ann Surg,1999, 230(1):9-11
[71] Rossi S,Di Stasi M, Buscarini E,et al.Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol,1996, 167(3): 759-768
[72] Rossi S,Di Stasi M, Buscarini E ,et al. Percutaneous radioffequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am, 1995,1:73
[73] Wong SL, Edw ards MJ, Chao C, et al.Radiofrequency ablation for unresectable hepatic tumors [J]. Am J Surg, 2001,182(2): 552- 557
[74] 别府透，土居浩一，石河隆敏，他．大肠癌肝转移局所凝固疗法[J]．日本外科学会杂志，2001，102(5)：390-397
[75] Tateishi R, Shiina S,Teratani T,et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer, 2005, 103(6): 1201-9.
[76] Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology, 2005, 234:961-967
[77] Machi J, Bueno RS. Wong LL. Long-term Follow-up Outcome of Patients Undergoing Radiofrequency Ablation for Unresectable Hepatocellular Carcinoma. World J surg,2005,29:1-10
[78] Chen MS, Li JQ, Zheng Y,et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Ann Surg, 2006,243: 321-328.
[79] Seki T, Wakabayashi M, Nakagawa T,et al.Percutaneous microwave coagulation therapy for patients w ith small hepatocellular carcinoma,comparison with percutaneous ethanol injecton therapy [J].Cancer, 1999,85(8): 1694-1702
[80] Ikeda M, Okada S,Ueno H,et al.Radiofrequency ablation and percutaeous ethanol injection inpatients with small hepatocellualr carcinoma: a comparative study[J].Jpn J Clin O ncol,2001,31(7):322-326
[81] Shinna S,TerataniT,ObiS,etal.Nonsurgicalt reatment of hepatocellular carcinoma:from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation[J].Oncolgy,2002,62(suppl):64-68
[82] Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma-4 cm.Gastroenterology, 2004, 127:1714-1723
[83] Shiina S, Teratani T, Obi S, et al. A randomized controlled study of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 2005,129:122-130
[84] Lin Sm, Lin CJ, Lin CC, et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection and percutaneous acetic acid injection to treat hepatocellular carcinoma 3 cm or less. Gut, 2005,54:1151-1156
[85] Tabuse K.A new operative procedure of hepatic surgery using amicrowave tissue coagulator.Arch Jpn Chir, 1979,48(2): 160-172
[86] Seki T,Wakabayashi IVLNakagawa T,et al.Ultrasonocally guided percutaneous microwave coagulation therapy foe small hepatocellular carcinoma.Cancer,1994, 74 (3): 817-825
[87] Dong BW, Zhang J, Liang P, et al.Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma.Int J Hyperthermia, 2003, 19(2): 119-33
[88] Zhang J, Dong B,Liang P, et al.Significance of changes in local immunity in patients with hepatocellular carcinoma alter percutaneous microwave coagulation therapy.Chin Med J(Engl),2002,115(9)
[89] Sato M, Watanabe Y, Ueda S, et al.Microwave coagulation therapy for hepatocellular carcinoma.Gastroenterology, 1996,110 : 1507-1514
[90] Ido K, Isoda N, Kawamoto C, et al.Laparoscopic microwave coagulation therapy for solitary hepatocellular carcinoma performed under laparoscopic ultrasonograpgy. Gastrointest Endosc, 1997,45:415- 420
[91] Seki S; Sakaguchi H; Iwai S; et al.Five-year survival of patients with hepatocellular carcinoma treated with laparoscopic microwave coagulation therapy. Endoscopy,2005,37(12): 1220-1225
[92] 梁萍，董宝纬，于晓玲，等．双电极植入式微波辐射三维热场的研究．中华超声影像学杂志，1999，8(4)：255-插页2
[93] 张晶，董宝纬，梁萍，等．原发性肝癌经皮微波治疗前后局部免疫活性细胞功能检测．中华医学杂志，2001，81(16)：974-977
[94] Ohmoto K, Mimura N, Iguchi Y, et al. Percutaneous microwave coagulation therapy for superficial hepatocellular carcinoma on the surface of the liver. Hepatogastroenterology,2003, 50(53): 1547-51
[95] Takamura M, Murakami T, Shibata T, et al.Microwave Coagulation Therapy with Interruption of Hepatic Blood In- or Outflow:An Experimental Study. J Vasc Interv Radiol,2001,12:619-622
[96] Ishida T, Murakami T, Shibata T, Inou Y, et al.Percutaneous Microwave Tumor Coagulation for Hepatocellular Carcinomas with Interruption of Segmental Hepatic Blood Flow. J Vasc Interv Radiol, 2002,13:185-191
[97] Shibata T, Iimuro Y, Yamamoto Y, et al . Small hepatocellular carcinoma: Comparison of radiofrequency ablation and percutaneous microwave coagulation therapy. Radiology,2002,223:331
[98] Goldberg SN. Comparison of techniques for image-guided ablation of focal liver tumors. Radiology,2002,223:304
[99] Dong B,Liang P, Yu X, et al.percutaneous sonographically guided microwave coagulation therapy for hepatocellular carcinoma:results in 234 patients.AJR, 2003, 180(6): 1547-1555
[100] Lu MD ,Chen JW, Xie XY, et al. Hepatocellular carcinoma:US-guided percutaneous microwave coagulation therapy.Radiology,2001,221:167-172
[101] Murakami R, Yoshimatsu S,Yamashita Y, et al. Treatment of hepatocellular carcinoma: value of percutanous microwave coagulation. AJR, 1995,164:1159-1164
[102] Sato M, Watanabe Y, Kashu Y, et al.Sequential percutaneous microwave coagulation therapy for liver tumor. Am J Surg, 1998,175(4):322-324
[103] Seki T, Tamai T, Nakagawa ZT, et al. Combination therapy with transcatherter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma.Cancer,2000,89:1245-1251
[104] 姜晓龙，孙巍，贾奇志，等．超声引导微波热凝固结合肝动脉栓塞化疗治疗肝癌．中华超声影像学杂志，2002，11：13-15
[105] Seki T,Wakabayashi M, Nakagawa T,et al.Percutaneous micrwave coagulation therapy for patients with small hepatocellular carcinoma:comparison with percutaneous ethanol injection therapy.Cancer, 1999, 85(8): 1694-1702
[106] Shibata T,Limuro Y, Yamamoto Y, et al. Small Hepatocellular carcinoma: comparison of radiofrequency ablation and percutaneous microwave coagulation therapy.Radiology,2002, 223:331-337
[107] Kurokochi K, Watanabe S, Masaki K, et al.Combined use of percutaneous ethanol injection and radiofrequcncy ablation for the effective treatment of hepatocellular carcinoma [J].lnt J Oncol,2002,21 (4):841-846
[108] Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol,2003,9(9): 1885-1891
[109] Bloomston M, Binitie O, Fraiji E, et al. Transcatheter arterial chemoemblization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy [J].Am Surg, 2002,68(9):828-831